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ABSTRACT 
Jacob Sinex 
CYCLING ENDURANCE PERFORMANCE AND PERIPHERAL MUSCLE 
FATIGUE FOLLOWING MARINE LIPID FRACTION PCSO-524™ SUPPLEMENTATION 
AND ECCENTRIC EXERCISE IN UNTRAINED MALES 
INTRODUCTION: Intensive or unaccustomed eccentric exercise is known to cause 
exercise-induced muscle damage (EIMD) commonly resulting in delayed onset muscle 
soreness (DOMS). EIMD/DOMS can result in decrements in endurance and resistance 
exercise performance. Although many treatments have been investigated for the prevention 
and alleviation of EIMD/DOMS, success has been limited. PCSO-524™ marine lipid fraction 
has been found to attenuate symptoms of inflammatory diseases such as arthritis and asthma, 
and thus may be a viable intervention to reduce inflammation-related EIMD/DOMS. 
PURPOSE: The purpose of this study was to evaluate the effects of PCSO-524™ 
supplementation on cycling endurance performance, peripheral muscle fatigue, muscle 
soreness and muscle damage following eccentric exercise. METHODS: Subjects were thirty-
two healthy, untrained men aged 18 – 26 who had not previously exercised for more than 
three times per week for 30 minutes each session for the past 90 days and had not participated 
in resistance training during the previous 60 days. Subjects were randomly assigned to 
consume 8 capsules PCSO-524™ (800 mg olive oil, 400 mg lipid extract) daily or olive oil 
(1200 mg) placebo for 30 days. Subjects completed three 20 minute cycling time trials (TT), 
thirty days of PCSO-524™ or placebo supplementation, a 20 minute downhill run (DHR) at -
16% grade after 26 days of supplementation and potentiated quadriceps twitch force (Qtw,pot) 
measures before and after the latter two TT. Each subject completed a familiarization TT, a 
pre-supplementation TT and a TT 24 hours following DHR. DOMS was measured via 11 
point pain scale at baseline, following supplementation and 24, 48, 72 and 96 hours following 
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DHR. Slow skeletal troponin I (sTnI) was measured pre-supplementation, post-
supplementation and following DHR at 0, 2, 24, 48, 72 and 96 hours. RESULTS: Cycling 
time trial performance was not significantly affected by DHR for PCSO-524™ (F = .106, p = 
.749) or placebo (F = .122, p = .732) groups. No significant differences were found in mean 
power output between PCSO-524™ and placebo groups. PCSO-524™ attenuated DOMS 
significantly at 72 hours (T = 2.48, p < .05; 95% CI = 0.3 – 2.6), and 96 hours post-run (T = 
2.1, p < .05; 95% CI = 0.04 – 2.7). Qtw,pot decreased for the placebo group following DHR (T 
= 2.095, p < .05), but did not change significantly for the PCSO-524™ group (T = .38, p > 
.05). Serum sTnI was significantly (p < .05) lower in the PCSO-524™ group at 2, 24, 48, 72 
and 96 hours post-DHR.  CONCLUSIONS: Thirty days of PCSO-524™ supplementation 
does not improve cycling endurance performance in untrained men after eccentric exercise 
compared to placebo. Thirty days of PCSO-524™ supplementation reduces muscle soreness 
following eccentric exercise, peripheral quadriceps fatigue in EIMD-affected muscles after 
endurance exercise and muscle damage following eccentric exercise.   
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CHAPTER 1  
INTRODUCTION 
Intensive or unaccustomed eccentric exercise is known to cause acute exercise-
induced muscle damage (EIMD) commonly resulting in delayed onset muscle soreness 
(DOMS). After an intensive or unaccustomed bout of eccentric exercise, a dull, aching pain 
combined with stiffness peaks around 24 – 48 hours and typically is resolved in 5 – 7 days 
(Tiidus, 2008). Typical types of exercise that may be expected to induce DOMS include any 
exercise with an eccentric component, such as repeatedly lowering a heavy weight, running 
downhill, repeated vertical jumping or bench stepping exercises. Several hypotheses have 
been proposed to explain the cause of DOMS including lactic acid, muscle spasm, connective 
tissue damage, muscle damage, inflammation and enzyme efflux theory (Cheung, Hume, & 
Maxwell, 2003). It is clear that none of these hypotheses alone is sufficient to fully explain 
DOMS. The current consensus is that these factors may each contribute to DOMS to some 
degree (Armstrong, 1984; Lewis, Ruby, & Bush-Joseph, 2012). 
DOMS symptoms generally occur 24-48 hours following an initiating event causing 
exercise-induced muscle damage and resolve in about 5 – 7 days post-exercise (Cheung et al., 
2003). Several stages of EIMD contribute to the symptoms felt during DOMS including the 
initiating event, inflammatory response and repair processes. EIMD is characterized by 
disruptions of the muscle fiber including “(a) disruption of the sarcolemma, (b) swelling or 
disruption of the sacrotubular system, (c) distortion of the contractile components of the 
myofibrils, (d) cytoskeleton damage, and (e) extracellular muscle fiber matrix abnormalities” 
(Beck et al., 2007). EIMD is a process that begins with the initiating event and proceeds 
through a series of inflammatory responses, cellular restructuring and eventual repair. 
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DOMS has been shown to be related to changes in muscle and joint function, 
characterized by altered functional perception, decreases in strength and power, and altered 
muscle recruitment patterns (Cheung et al., 2003). Subjects experiencing DOMS after 
performing 50 maximal eccentric repetitions using their forearm flexors had impaired force 
perception and joint angle perception using the exercised arm (Saxton et al., 1995). Altered 
motor unit recruitment patterns have been characterized by changes in joint angles while 
running with DOMS (Goff, Hamill, & Clarkson, 1998). Strength and power decrements 
during DOMS have been widely reported (Donnelly, Maughan, & Whiting, 1990; R G Eston, 
Mickleborough, & Baltzopoulos, 1995; Kazunori Nosaka, Newton, & Sacco, 2002). 
Much of the literature related to EIMD/DOMS and exercise performance has focused 
on the loss of muscle strength that occurs immediately following muscle damage and eventual 
recovery to baseline. Decrements in endurance exercise performance due to DOMS/EIMD 
has also been established. The first study to directly demonstrate a significant effect of EIMD 
on endurance performance in humans, Marcora and Bosio (2007), found that self-paced 
running time trial performance was reduced by 4% (p < .01) following eccentric exercise 
compared to baseline, while perceived exertion was not different between trials. Twist and 
Eston (2009) observed that 5 minute time trial performance on a cycle ergometer was 
significantly (p < .05) reduced at 48 hours after an eccentric exercise protocol consisting of 
100 counter-movement vertical jumps. Davies et al. (2009) investigated cycling performance 
following squat exercise and found reduced time-to-exhaustion during severe exercise. 
Doncaster and Twist (2012) found that time-to-exhaustion in arm cranking exercise was 
reduced following bench press exercise. 
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While significant effort has been put into investigating therapies to reduce muscle 
damage due to exercise and to alleviate DOMS symptoms after EIMD has occurred, relatively 
little success in reducing EIMD and DOMS can be found in the literature. Previously 
investigated treatment methods include “cryotherapy, stretching, anti-inflammatory drugs, 
ultrasound, electrical current techniques, homeopathy, massage, compression, hyperbaric 
oxygen and exercise” (Cheung et al., 2003). 
Among treatments that have been investigated, non-steroidal anti-inflammatory drugs 
(NSAIDs) have shown some beneficial effects in alleviating DOMS. Researchers have 
reported reduced soreness at 48 hours post-exercise for a treatment group taking ibuprofen, 
dexamethasone and aspirin, but no differences in muscle strength between treatments (Hasson 
et al., 1993; Hasson, Wible, Reich, Barnes, & Williams, 1992). Other data include less 
impairment of elbow extension in subjects taking aspirin before and following eccentric 
exercise (Francis & Hoobler, 1987). NSAIDs inhibit arachidonic acid metabolism through the 
cyclooxygenase pathway and prevent the production of pro-inflammatory prostaglandins, 
which are involved in the immune system response that can lead to secondary muscle damage 
(Warden, 2009). Arachidonic acid metabolism and the production of pro-inflammatory 
proteins is also important in conditions such as asthma (Mickleborough & Rundell, 2005) and 
arthritis (Simopoulos, 2002).  
Nutritional supplementation of treatments containing omega-3 polyunsaturated fatty 
acids (ω3FA) such as fish oil and PCSO-524™  have been found to alleviate symptoms of a 
number of inflammation-related disease states such as asthma (Broughton, Johnson, Pace, 
Liebman, & Kleppinger, 1997), exercise-induced bronchoconstriction (Mickleborough, 
Murray, Ionescu, & Lindley, 2003; Mickleborough, Vaughn, Shei, Davis, & Wilhite, 2013), 
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rheumatoid arthritis (Kremer et al., 1990) and osteoarthritis (Knott, Avery, Hollander, & 
Tarlton, 2011). Data from previous research has shown that ω3FA supplementation can 
attenuate markers of delayed onset muscle soreness resulting from intensive exercise (Sen et 
al., 1997; Tartibian, Maleki, & Abbasi, 2009), can attenuate post-exercise rise in protein 
release from muscle cells (Ernst, Saradeth, & Achhammer, 1991) and attenuate post-exercise 
immunosuppression (Benquet et al., 1994). 
A marine lipid extract that has shown results in terms of reducing inflammation is 
PCSO-524™ (Lyprinol®/Omega XL®), a nutritional supplement derived from the New 
Zealand green-lipped mussel (Perna Canaliculus) containing a mixture of triglycerides, sterol 
esters, sterols, polar lipids, free fatty acids and carotenoids (Doggrell, 2011). Supplementation 
with PCSO-524™ has been shown to reduce symptoms in several inflammation-related 
conditions including osteoarthritis (Gibson & Gibson, 1998), rheumatoid arthritis (Gibson & 
Gibson, 1998), asthma (Emelyanov et al., 2002) and exercise-induced bronchoconstriction 
(Mickleborough, Vaughn, Shei, Davis, & Wilhite, 2013) in human clinical trials. PCSO-524™ 
has shown to have effects in animal models of inflammation including reduced swelling 
associated with collagen type-II-induced arthritis in rats (Wakimoto et al., 2011; Whitehouse 
et al., 1997). Similarly to NSAIDs, the mechanism by which PCSO-524™ affects 
inflammatory processes includes inhibition of the cyclooxygenase pathway and the 5-
1ipoxygenase pathway (Whitehouse et al., 1997). PCSO-524™ may have additional anti-
inflammatory and anti-oxidant effects through furan fatty acids, which have been identified in 
the extract and found to reduce swelling in a rat adjuvant arthritis model (Wakimoto et al., 
2011). 
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Recently, PCSO-524™ supplementation has been investigated as treatment for 
EIMD/DOMS following intensive exercise with equivocal results. Pumpa et al. (2011) 
investigated the effects of PCSO-524™ supplementation on measures of muscle damage 
following eccentric exercise using 20 well-trained men as subjects. Muscle damage was 
induced with five bouts of eight minutes of downhill running at 80% of HRmax at -10% incline 
with two minutes of level walking between bouts.  No significant differences (p > .05) were 
found between treatment and placebo groups for any of the measured outcome variables 
including visual analogue scale of DOMS pain, pressure sensitivity, thigh circumference, 
range of motion of the knee, isokinetic force, vertical jump, IL-1, IL-10, IL-6, tumor necrosis 
factor α, C - reactive protein, myoglobin and creatine kinase. The authors noted they observed 
little evidence of an inflammatory response following eccentric exercise in either treatment or 
placebo subjects. Without an inflammatory response, which is the proposed mechanism that 
PCSO-524™ may affect, it is unlikely that PCSO-524™ supplementation would result in 
differences between groups. 
In contrast to the data of Pumpa et al. (2011), Baum et al. (2013) found PCSO-524™ 
supplementation resulted in less DOMS in recreational runners following a 30 km run 
compared to their soreness levels following a previous 30 km prior to treatment. The PCSO-
524™ group experienced reduced soreness following their post-treatment run compared to the 
pre-treatment run (median pain score: 3.5 pre-treatment, 2.0 post-treatment) compared to no 
changes in the control group. Runners who trained fewer than three times per week 
experienced greater attenuation of muscle soreness compared to subjects who ran more 
frequently. In this study (Baum et al., 2013), PCSO-524™ had greater effects in subjects who 
were less well adapted to the exercise task. 
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In addition to potential attenuation of EIMD/DOMS, ω3FA supplementation has been 
investigated for effects toward improving exercise performance (Mickleborough, 2013; 
Tiryaki-Sönmez, Schoenfeld, & Vatansever-Ozen, 2011). A number of studies have shown a 
theoretical basis for the improvement of exercise performance through enhanced red blood 
cell deformability (Cartwright, Pockley, Galloway, Greaves, & Preston, 1985; Terano et al., 
1983), reduction in fat mass (Hainault & Carlotti, 1993; A. M. Hill, Buckley, Murphy, & 
Howe, 2007; Malaguti, Baldini, Angeloni, Biagi, & Hrelia, 2008), enhanced lipid metabolism 
(Jump, Clarke, Thelen, & Liimatta, 1994; Raclot, Groscolas, Langin, & Ferré, 1997), reduced 
heart rate during submaximal exercise (Buckley, Burgess, Murphy, & Howe, 2009; Peoples, 
McLennan, Howe, & Groeller, 2008), enhanced mitochondria biogenesis (Flachs et al., 2005; 
Vaughan, Garcia-Smith, Bisoffi, Conn, & Trujillo, 2012) and improved fatigue resistance in 
isolated hindlimb muscles in rats (Peoples & McLennan, 2010, 2013).  
Mitochondrial density and skeletal muscle oxidative capacity are related to endurance 
exercise performance (Hoppeler & Fluck, 2003). Untrained subjects can increase 
mitochondrial volume after a few weeks of endurance training and improve maximal aerobic 
exercise capacity (Hoppeler et al., 1985). There is evidence that ω3FA supplementation may 
be able to induce similar adaptation in skeletal muscle. ω3FA can increase mitochondrial 
biogenesis and increase metabolism in skeletal muscle cells in vitro (Vaughan et al., 2012). 
ω3FA were found to upregulate glycolytic, oxidative and total metabolism and increase 
mitochondrial content in isolated cells. In a different study, ω3FA were found to enhance 
expression of genes for mitochondrial proteins and enhance β-oxidation in white fat cells in 
mice (Flachs et al., 2005). 
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Reduced heart rate during exercise has been found in ω3FA supplementation studies of 
elite Australian rules football players (Buckley et al., 2009) and well-trained male cyclists 
(Peoples et al., 2008). Buckley et al. (2009) observed reduced heart rate while running at 10 
km/hr (p = 0.05) after five weeks of fish oil supplementation (1.56 g DHA, 0.36 g EPA per 
day). Peoples et al. (2008) supplemented nine well-trained male cyclists with eight capsules of 
fish oil (2.4 g DHA, 0.8 g EPA) per day for eight weeks. Heart rate during incremental 
workloads on a cycle ergometer to exhaustion (including peak heart rate) were reduced with 
no reduction in peak power output. These findings suggest that fish oil supplementation may 
enhance oxygen metabolism during exercise and reduce the work required of the 
cardiovascular system. In a rat model, oxygen consumption was lowered by ω3FA 
supplementation during isolated hindlimb stimulation (Peoples & McLennan, 2013), which 
provides support for these findings. 
Body composition is an important contributing factor in endurance exercise, especially 
in those events which require locomotion of one’s body on an uphill or non-level terrain such 
as many cycling and running competitions. ω3FA supplementation has been studied for 
potential effects on body composition in several different populations including athletes, 
sedentary normal weight people and overweight people (A. M. Hill et al., 2007; Malaguti et 
al., 2008; Warner Jr & Ullrich, 1989). While the results do not conclusively prove that ω3FA 
supplementation alone reduces body weight, there is some evidence that it is effective in 
combination with exercise in improving body composition. 
Hill et al. (2007) found fish oil supplementation combined with exercise resulted in 
lowered body fat compared with sunflower oil combined with exercise in hyperlipidemic 
subjects. The subjects supplemented with 6 g fish oil per day (1.56 g DHA, 0.36 g EPA) or 
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placebo (6 g sunflower oil) for 12 weeks. Half of the fish oil subjects (n=19) were assigned a 
three-times per week exercise regimen while half did not exercise (n=18). The placebo group 
was divided into exercise (n=18) and non-exercise (n=19) groups as well. In a similar study, 
Warner et al. (1989) found that fish oil and exercise resulted in lowered body fat composition 
compared to baseline and fish oil without exercise. However, this study did not include an 
exercise only trial so it is not known if fish oil supplementation provided an additional benefit 
over exercise only. 
Human studies on the ergogenic effects of ω3FA for endurance exercise performance 
are limited and findings equivocal. Only a few studies have directly investigated the effect of 
ω3FA consumption on endurance exercise performance. Buckley et al. (2009) did not observe 
differences between the fish oil and placebo groups in time to exhaustion during running at 
the subject’s 2200 m time-trial speed. Nieman et al. (2009) similarly did not find a significant 
effect from fish oil supplementation (2 g EPA, 0.4 g DHA per day for six weeks) on 10 km 
cycling time trial performance or measures of inflammation and muscle damage (plasma 
cytokines, serum C-reactive protein, creatine kinase. Whether PCSO-524™ supplementation 
affects endurance exercise performance has not been investigated. 
In conclusion, there is evidence to suggest that treatments such as PCSO-524™ that 
inhibit COX and 5-LOX pathways may be effective in reducing symptoms of DOMS 
following intensive exercise (Baum et al., 2013; Tartibian, Maleki, & Abbasi, 2011). 
Additionally, ω3FA are able to modify several factors related to exercise performance 
including body composition, lipid oxidation, mitochondrial biogenesis and oxidative 
metabolism (Mickleborough, 2013; Tiryaki-Sönmez et al., 2011). PCSO-524™ has been 
shown to inhibit the COX and 5-LOX pathways, contains ω3FA in high concentration and 
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therefore may enhance mechanisms to improve endurance-exercise performance while 
EIMD/DOMS is being experienced. The present study investigated the relationship between 
PCSO-524™ supplementation, EIMD/DOMS, peripheral muscle fatigue and endurance 
exercise performance. 
Statement of the Problem 
ω3FA consumption has been investigated as a potential ergogenic aid during exercise 
and for anti-inflammatory effects in various disease states and during DOMS. Endurance 
exercise performance can be reduced following eccentric exercise, as a result of EIMD and 
symptoms of DOMS. EIMD is associated with a number of changes in muscle, including 
increased inflammation. Though inflammation due to damage is expected and part of the 
healing process, unchecked inflammation may cause additional muscle damage and prolong 
the recovery process. PCSO-524™ is a nutritional supplement containing ω3FA and furan 
fatty acids that has been shown to be effective in attenuating symptoms of inflammation-
related diseases and may be an effective treatment for exercise-related inflammation. To date, 
no published research has investigated the effects of PCSO-524™ supplementation on 
endurance exercise performance and DOMS/EIMD in untrained subjects. This study 
investigated the effects of PCSO-524™ (Lyprinol®/Omega XL®) supplementation on 
endurance performance, DOMS, peripheral muscle fatigue and muscle damage in untrained 
men following eccentric exercise. 
Purpose of the Study 
The purpose of this study was to evaluate whether EIMD-related endurance exercise 
performance impairment, peripheral muscle fatigue and symptoms of DOMS in untrained 
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men following eccentric exercise is affected by PCSO-524™ marine lipid fraction 
supplementation.  
Delimitations 
Healthy, untrained men were recruited as volunteer subjects for this study. Subjects 
were recruited on the Indiana University campus via flyers, campus online classifieds and 
word-of-mouth. Data collection occurred in a laboratory setting where temperature, humidity 
and barometric pressure are relatively unchanging. Cycling performance tests were conducted 
on an electronically braked cycle ergometer with seat height and handlebar height set to the 
subject’s preferences. A familiarization time trial was conducted to minimize learning effects 
and variability during experimental trials. Subjects were asked to refrain from caffeine and 
alcohol consumption 24 hours prior to study visits. Subjects were asked to maintain their 
normal diet and sleep routine for the duration of the study, to limit non-study exercise and be 
well-rested and hydrated prior to exercise tests. Subjects were asked to refrain from using 
anti-inflammatory medications or nutritional supplements during the study, and from 
participating in eccentric-type exercise training. 
Limitations 
The subjects were self-selected based on their exposure to study recruitment methods 
and their desire to participate in the study. The treadmill was custom modified to run in 
reverse to enable downhill running and a handrail was installed to provide safety for the 
subjects. Due to the size of the treadmill belt and the nature of this unusual activity, it was 
possible that subjects did not run with the same running mechanics that they would have used 
while running outside down a similar slope. Subjects were asked to perform to their fullest 
ability during the cycle ergometer time trial. However, it is not possible to know if subjects 
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performed to the best of their ability. Subjects were asked to limit their exercise habits during 
the study. Exercise activity was self-reported, but it is not possible to know to what degree the 
responses reflect the subjects’ actual activity. Subjects were asked to record their 
supplementation intake and return any unused capsules. It is not possible to know if subjects 
consumed all of the capsules that they reported consuming. The cycle ergometer positioning 
was adjusted to the subject’s preference based on starting adjustment suggested by an 
investigator. Many subjects had little or no previous cycling experience and may not have 
selected at optimal position, resulting in biomechanical impairments to their performance.  
Assumptions 
Subjects refrained from changing their exercise participation rate in order to improve 
performance in subsequent performance tests. Subjects remained on their normal diet and 
sleep patterns. Subjects refrained from caffeine and alcohol prior to performance tests and 
were well-rested and hydrated before performance tests. The downhill running protocol is 
valid for producing exercised-induced muscle damage in the subject population studied. The 
downhill running protocol would induce sufficient EIMD and DOMS to reduce subsequent 
time trial performance. Subjects were highly motivated to maintain the highest possible level 
of performance during cycle ergometer time trials. The cycle ergometer time trial protocol is a 
valid measure of endurance exercise performance in untrained men. The cycle ergometer time 
trial protocol would cause peripheral muscle fatigue in the quadriceps. 
Hypotheses 
The study was designed to test the following hypotheses: 
1. Twenty minute cycling time trial mean power output will be greater in the PCSO-
524™ supplementation group compared to the placebo group after eccentric exercise. 
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2. Potentiated quadriceps twitch force will decrease less following a 20 minute cycling 
time trial in the PCSO-524™ supplementation group compared to the placebo group. 
3. The concentration of skeletal troponin I (sTnI) in blood will be lower in the PCSO-
524™ supplementation group compared to the placebo group following eccentric 
exercise. 
4. Perceived quadriceps soreness during squatting will be lower in the PCSO-524™ 
supplementation group compared to the placebo group following eccentric exercise. 
Definition of Terms 
Delayed Onset Muscle Soreness (DOMS) - “DOMS is the sensation of discomfort or 
pain in the skeletal muscles that occurs following unaccustomed muscular exertion.” 
(Armstrong, 1984) 
Exercise-induced Muscle Damage (EIMD) - Muscle damage following strenuous or 
unaccustomed exercise. Characterized by DOMS, strength loss, disruptions of myofibrillar 
structure and inflammation. (Paulsen, Mikkelsen, Raastad, & Peake, 2012) 
Half maximal inhibitory concentration (IC50) - Concentration of a compound 
required to inhibit a biological process by 50% in vitro (Griffiths & Sundaram, 2011) 
Omega-3 polyunsaturated fatty acids (ω3FA) - Polyunsaturated fatty acids where 
the first double bond from the methyl (CH3) end of the molecule is located between the third 
and fourth carbons. (Ruxton, Reed, Simpson, & Millington, 2004) 
Oxygen consumption (VO2) – rate of oxygen consumption, the volume of oxygen 
consumed in one minute 
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PCSO-524™ (Lyprinol®/Omega XL®) - A stabilized lipid extract of the New 
Zealand green-lipped mussel. Manufactured and distributed by Pharmalink International. 
(Tenikoff, Murphy, Le, Howe, & Howarth, 2005) 
Polyunsaturated fatty acids (PUFA) - Fatty acids containing two or more C=C 
double bonds. PUFA are named based on the position of C=C double bonds and their total 
length. (Ruxton et al., 2004) 
Potentiated quadriceps twitch force (Qtw,pot) - Quadriceps muscle twitch measured 
following a short (usually 5 second) maximal voluntary contraction and, in this study, induced 
via magnetic stimulation. (Amann, Pegelow, Jacques, & Dempsey, 2007)  
Power – the rate of mechanical work done, measured in watts (expressed as work / 
time) 
Rating of perceived exertion (RPE) – a category scale of rating for perception of 
exertion ranging from 6 (no exertion) to 20 (maximal exertion) (Borg, 1982) 
Time trial – a self-paced cycling exercise in which the participant attempts to attain 
the highest possible average power 
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CHAPTER 2 
REVIEW OF LITERATURE 
PCSO-524™ 
PCSO-524™, marketed under the brand names Lyprinol® and Omega XL®, is a 
nutritional supplement extracted from the New Zealand green-lipped mussel (Perna 
Canaliculus) containing a mixture of triglycerides, sterol esters, sterols, polar lipids, free fatty 
acids and carotenoids (Doggrell, 2011). PCSO-524™ came into research interest in part due 
to folklore that coastal Maori, a group of people native to New Zealand, suffered from lower 
incidences of arthritis than the general New Zealand population and inland Maori. Coastal 
Maori consume the green-lipped mussel as part of their normal diet as a contributor to good 
health (Cobb & Ernst, 2006).  
Each capsule of PCSO-524™ contains 50 mg lipid extract, 100 mg olive oil and 0.225 
mg vitamin E (d-α-tocopherol). Lipids from five major classes including sterol esters (230 
mg/mL), triglycerides (43 mg/mL), free fatty acids (260 mg/mL), sterols and polar lipids (23 
mg/mL) are found in PCSO-524™. PCSO-524™ contains approximately 140 mg/mL 
eicosapentaenoic acid (EPA, 20:5) (21% by weight) and 87 mg/mL docosahexaenoic acid 
(DHA, 22:6) (13% by weight). Ninety-one fatty acid components have been identified 
including 5,9,12,15-octodecatretraenoic acid, 5,9,12,16-nondecatertraenoic acid, 7,11,14,17-
eicosatetraenoic acid, 5,9,12,15,18-heneicsapententaenoic acid, myristic acid, palmitic acid, 
palmitoleic acid, stearic acid and oleic acid (Wolyniak, Brenna, Murphy, & Sinclair, 2005). 
Researchers have investigated P. Canaliculus and products derived from it such as 
Seatone™ and PCSO-524™ for evidence of therapeutic effects on inflammatory-related 
conditions. P. Canaliculus was first observed to have effects on joint stiffness and pain in a 
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study designed to determine if the mussel had an effect on cancer outcomes (Croft, 1986). 
PCSO-524™ has been investigated extensively as a treatment for various inflammatory 
conditions including asthma (Emelyanov et al., 2002), exercise-induced bronchoconstriction 
(Mickleborough et al., 2013), a mouse model of allergic airways disease (Wood, Hazlewood, 
Foster, & Hansbro, 2010), experimentally-induced inflammatory bowel disease (Tenikoff et 
al., 2005) and a rat model of adjuvant-induced arthritis (Wakimoto et al., 2011). 
Emelyanov et al (2002) investigated the effects of eight weeks of PCSO-524™ 
supplementation on symptoms of asthma including daytime wheeze, waking at night from 
asthma, daily use of short acting inhalers. Additionally, lung function tests were performed 
and exhaled hydrogen peroxide concentration, a marker of airway inflammation, was 
measured. Subjects received four capsules (200 mg active lipid extract) of PCSO-524™ or 
placebo per day for eight weeks. Subjects taking PCSO-524™ had lower daytime wheeze, 
higher morning peak expired flow and lower exhaled H2O2 concentration. The authors 
concluded that PCSO-524™ may have beneficial effects in patients with steroid-naïve atopic 
asthma. 
The findings of Mickleborough et al. (2013) provide support for effectiveness of 
PCSO-524™ in the treatment of exercise-induced bronchoconstriction. Twenty subjects 
participated in randomized crossover trial, receiving three weeks of eight capsules (400 mg 
active lipid extract) per day of PCSO-524™ supplementation or placebo. After a two week 
washout period, subjects switched treatments and supplemented for three more weeks. PCSO-
524™ supplementation improved a number of measures of airway inflammation and excise-
induced bronchoconstriction symptoms. PCSO-524™ subjects were found to have reduce 
bronchodilator use, attenuated reduction in forced expired volume in one second (FEV1) 
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following a eucapnic voluntary hyperventilation trial, improved combined morning and 
evening peak flow, and reduced markers of inflammation in exhaled breath condensate. 
Recent research has investigated the effects of PCSO-524™ in exercise states that may 
be affected by inflammation, particularly in relation to DOMS. Pumpa et al. (2011) 
investigated the effects of PCSO-524™ supplementation on measures of muscle damage 
following eccentric exercise in 20 well-trained men. Subjects were divided into two groups of 
ten and the subjects consumed 200 mg (4 capsules) of PCSO-524™ or an olive oil capsule 
placebo daily for a period of eight weeks. Following the supplementation period, each subject 
performed a downhill running protocol designed to induce muscle damage. No significant 
differences were found between groups on the measured outcomes, which included 
“performance measures (Kin-Com, counter movement and squat jump), pain assessments 
(visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, 
Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) … 
assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run)” 
(Pumpa et al., 2011). 
Baum et al. (2013) found that PCSO-524™ supplementation had an effect on DOMS 
symptoms following a 30km run by recreational runners. The PCSO-524™ group experienced 
reduced soreness following their post-treatment run compared to the pre-treatment run 
(median pain score: 3.5 pre-treatment, 2.0 post-treatment) compared to no changes in the 
control group (median pain score: 2.0 pre-treatment, 2.0 post-treatment). Median pre-
treatment pain scores in the control group were not different from post-treatment pain scores 
in the PCSO-524™ group. The authors reported that the greatest differences in DOMS were 
seen in runners who trained no more than three times per week (PCSO-524™ group post-
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supplementation run: 1.7 pain score, control group post-supplementation run: 4.0 pain score). 
This result suggests that PCSO-524™ supplementation may have the greatest benefit for the 
less well-trained athlete. Trained runners may experience less soreness from a long run due to 
being conditioned for the task. 
The primary mechanism by which PCSO-524™ is likely to affect muscle damage and 
recovery processes resulting from muscle damage is during the inflammatory response that 
occurs following EIMD. Following a muscle damaging event, intracellular [Ca2+] may be 
elevated due to increased cell membrane permeability (Nielsen, Madsen, Jørgensen, & Sahlin, 
2005). Phospholipase A2, the regulatory enzyme for the production of eicosanoids, is activated 
by increased [Ca2+], catalyzing a reaction that releases arachidonic acid (AA) from cell 
membranes. AA is precursor of eicosansoids including two-series prostaglandins (PGE2) and 
four-series leukotrienes (LT4) through a series of reactions catalyzed by cyclooxygenase and 
5-lipoxygenase (Figure 1) (Balsinde, Winstead, & Dennis, 2002; Gissel, 2005; 
Mickleborough & Rundell, 2005). 
PCSO-524™ acts as a “dual inhibitor of arachidonate oxygenation by both 
cyclooxygenase (COX) and 5-1ipoxygenase” with particular emphasis on the COX-2 pathway 
and has been shown to inhibit leukotriene B4 (LTB4) production in human neutrophils in vitro 
(Whitehouse et al., 1997). Whitehouse et al. (1997) determined that unfractionated PCSO-
524™ inhibits LTB4 production in vitro by isolating human polymorphonuclear leukocytes 
(PMN) and stimulating production of LTB4 through the addition of AA. In the presence of 
PCSO-524™, LTB4 production was not detectable compared to 19.8 ± 0.8 ng/106 PMN in the 
control PMN. Prostaglandin production was similarly inhibited in isolated PMN by PCSO-
524™ with IC50 = 1.2 µg/ml. 
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Figure 1: Diagram of arachidonic acid and eicosapentaenoic acid via the cyclooxygenase and 5-lipoxygenase 
pathways (Simopoulos, 2002) 
 
In addition to its effects on AA metabolism, PCSO-524™ contains furan fatty acids 
(Wakimoto et al., 2011), which can be incorporated into cell membranes to act as radical 
scavengers (Spiteller, 2005) and have been shown to have antioxidant effects in vitro (Okada 
et al., 1990). Furan fatty acids present in PCSO-524™ have been hypothesized as an 
overlooked component of the cardioprotective effects of diets containing high amounts of 
PUFAs including DHA and EPA (Spiteller, 2005). PCSO-524™ has been found to have 
similar anti-inflammatory properties to fish oil in a rat model of adjuvant arthritis at lower 
concentrations than fish oil required for anti-inflammatory effects (Whitehouse et al., 1997), 
suggesting that other components besides DHA and EPA contribute to its anti-inflammatory 
properties. In a study that compared PCSO-524™, EPA and isolated furan fatty acids in a 
similar rat arthritis model, furan fatty acids provided greater protective effects than EPA and 
similar to PCSO-524™ (Wakimoto et al., 2011).  
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PUFA Supplementation and Exercise Performance 
Omega-3 fatty acids (ω3FA) are polyunsaturated fatty acids containing a carbon-
carbon double bond at the third carbon from the end of the molecule. Omega-3 fatty acids 
have been investigated for their impact on health and various disease states including 
protection from cardiac disease (Lavie, Milani, Mehra, & Ventura, 2009; Saravanan, 
Davidson, Schmidt, & Calder, 2010), improvement in muscle protein synthesis in older adults 
(Smith et al., 2011), reduction in symptoms of inflammatory disease (Simopoulos, 2002) and 
improvement in mood state disturbance (Su, 2009). Fish oil and flaxseed oil are common 
sources of ω3FA that have been studied. EPA (a twenty carbon molecule with five carbon-
carbon double bonds) and DHA (a twenty-two carbon molecule with six carbon-carbon 
double bonds) are among the most-researched ω3FA. ω3FA have also been investigated for 
potential ergogenic effects during exercise. While results from animal studies are promising, 
results from human exercise studies are less clear. 
For long-distance migrant birds, fuel efficiency and highly effective oxidative 
metabolism are required to enable their strenuous seasonal journeys. One type of migrant bird, 
semipalmated sandpipers (Calidris pusilla, L.), prepares for a 3-day, ~4500km flight from 
eastern Canada to South America by feeding on amphipods containing high levels of ω3FA 
(Maillet & Weber, 2006, 2007; Weber, 2009). During their refueling stop in the Bay of Fundy 
(New Brunswick, CA), the birds consume a diet comprised of approximately 45% ω3FA 
(31% EPA, 14% DHA), doubling their body mass from ~20 g to 40 g in preparation for the 
flight. The consumption of ω3FA during this stop is important not only because lipids are a 
concentrated fuel source for the long distance traveler, but because dietary fatty acid 
composition is related to capacity for endurance exercise in animals. For example, endurance 
 
  
20 
 
exercise capacity is affected the dietary fatty acid composition in rats (Ayre & Hulbert, 1997), 
Atlantic salmon (McKenzie & Higgs, 1998) and migrant songbirds (Pierce, McWilliams, 
O’Connor, Place, & Guglielmo, 2005).  
In humans, the effect of fatty acid composition in the diet and ω3FA consumption on 
endurance exercise performance is less clear. Only a few studies have directly investigated the 
effect of ω3FA consumption on performance. Buckley et al. (2009) did not observe 
differences between the fish oil and placebo groups in time to exhaustion at the subject’s 2200 
m running time-trial speed. Nieman et al. (2009) similarly did not find a significant effect 
from fish oil supplementation (2 g EPA, 0.4 g DHA per day for six weeks) on 10 km cycling 
time trial performance or measures of inflammation and muscle damage (plasma cytokines, 
serum C-reactive protein, creatine kinase). 
The predominant effect of ω3FA supplementation that has been observed in humans 
during exercise is reduced heart rate during submaximal exercise (Buckley et al., 2009; 
Peoples et al., 2008). Fish oil supplementation has also been found to reduce heart rate at rest 
by 1.6 bpm in a meta-analysis (Mozaffarian et al., 2005). Buckley et al. (2009) observed 
reduced heart rate while running at 10km/hr (p = 0.05) after five weeks of fish oil 
supplementation (1.56 g DHA, 0.36 g EPA per day). Peoples et al. (2008) supplemented nine 
well-trained male cyclists with eight capsules of fish oil (2.4 g DHA, 0.8 g EPA) per day for 
eight weeks. Heart rate during incremental workloads on a cycle ergometer to exhaustion 
(including peak heart rate) were reduced with no reduction in peak power output. These 
findings suggest that fish oil supplementation may enhance cardiovascular efficiency during 
submaximal exercise.  
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Maintenance of red blood cell (RBC) deformability during exercise has been 
investigated in relation to ω3FA consumption. Deformability refers to “the ability of a body to 
change shape in response to a deforming force” (Chien, 1987). RBCs deform from their 
normal shape as they pass through the microcirculation (Chien, 1987). During exercise, RBC 
deformability can decrease (Van der Brug, Peters, Hardeman, Schep, & Mosterd, 1995), 
which can lead to increases in platelet aggregation and increased transit time the 
microcirculatory system (Yalcin, Bor-Kucukatay, Senturk, & Baskurt, 2000). ω3FA 
supplementation improves RBC deformability and decreases whole blood viscosity 
(Cartwright et al., 1985). It has been hypothesized that ω3FA supplementation may be able to 
help maintain RBC deformability during exercise, potentially improving oxygen delivery to 
the skeletal muscles and increasing exercise performance (Guezennec, Nadaud, Satabin, 
Leger, & Lafargue, 1989). 
The results of research on RBC deformability during exercise and ω3FA 
supplementation are inconclusive. Guezennec et al. (1989) found less reduction in RBC 
deformability after hypobaric exercise in subjects supplemented with 6 g fish oil (1.08 g EPA, 
.72 g DHA) for six weeks compared to placebo. However, there was no significant difference 
between groups in RBC deformability at rest. In contrast to these results, Oostenbrug et al. 
(1997) did not observe a change in RBC deformability characteristics during exercise and no 
change in cycling time trial performance after three weeks of supplementation with 6 g fish 
oil per day (1.08 g EPA, .72 g DHA). 
PUFA Supplementation and EIMD/DOMS 
Several studies have investigated the effects of PUFA supplementation on EIMD and 
DOMS, with equivocal results. Two studies from Tartibian et al. (2009, 2011) reported 
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improved inflammatory, pain and mobility measures in fish oil-supplemented subjects. The 
2009 study found attenuated range of motion decrements and less muscle soreness compared 
to placebo 48 hours after eccentric exercise in subjects who had taken 1 capsule (324 mg 
EPA, 216 mg DHA) per day for 30 days. The eccentric exercise protocol consisted of 40 
minutes of bench stepping in five minute increments followed by one minute rest. The 2011 
study found that fish oil supplementation moderated inflammatory and tissue injury markers 
following eccentric exercise. Experimental subjects demonstrated less increase in tumor 
necrosis factor α (TNF-α) and prostaglandin E2 (PGE2) following exercise, at 24 and 48 hours 
post-exercise. IL-6, CK and Mb levels were lower at 24 and 48 hours.   
In contrast to data from Tartibian et al. (2009, 2011), Lenn et al. (2002) did not 
observe significant differences due to fish oil and isoflavone supplementation on muscle 
soreness following eccentric exercise of arm extensors. After 30 days of supplementation of 
1.8 g/day fish oil (n=7), 120 mg soy isolate (n=8) or placebo (n=7), subjects performed 50 
maximal effort eccentric contractions at a rate of 90º/sec. Physical measurements included 
muscle soreness, upper arm circumference, range of motion, and isokinetic strength. Blood 
measurements were taken immediately after, 3 hours, 24 hours, 48 hours and 72 hours 
following exercise and tested for cortisol, creatine kinase (CK), interleukin-6 (IL-6), TNF-α, 
lipid peroxidation and serum iron. The investigators reported changes in range of motion, 
increased soreness, increased arm circumference and decreased strength across groups but no 
significant differences between groups. No significant changes were found in blood markers 
of muscle damage and inflammation. The relatively short duration of exercise and small 
muscle mass (relative to other studies that used leg muscles, for example) exercised in this 
study may explain the lack of detectable increase in IL-6. Also noted was a high level of 
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variability in CK among subjects, which limited its usefulness in detecting differences 
between groups. 
Additional data do support the hypothesis that the anti-inflammatory effects of PUFAs 
are relevant in exercise conditions. In a study using eccentric arm curl exercises to induce 
muscle damage, subjects supplementing with ω3FA reported attenuated weighted and fully 
extended arm soreness. Arm circumference, arm volume and arm skin surface temperature 
were also measured without significant differences. The design of this study used each subject 
as his/her own control, where a mixture of dominant and non-dominant arm were used for the 
treatment and control conditions. This design was incorporated to avoid a repeated bout effect 
while still enabling repeated-measures within subjects. One limitation of this study is the lack 
of a placebo group (Jouris, McDaniel, & Weiss, 2011).  
PUFA supplementation combined with other compounds has been found to reduce 
inflammation following arm curl exercises. Subjects supplemented with a dietary supplement 
containing DHA, tocopherols and flavonoids for 14 days had lowers levels of IL-6 and C-
reactive protein (CRP) at 10 days post-exercise (Phillips, Childs, Dreon, Phinney, & 
Leeuwenburgh, 2003). A plant extract containing high levels of omega-3 and various 
antioxidants also resulted in attenuated inflammatory markers including serum CK after 48 
hours, LDH after 24 and 48 hours, cortisol at 24 and 48 hours, IgA at 0, 24 and 48 hours, 
potassium at 24 and 48 hours. Pain scores were also lower in the treatment group at 48 hours 
(Meamarbashi & Abedini, 2011). 
Muscle Damage Processes and Inflammation 
Muscle damage induced by exercise and recovery is a complex process that is not yet 
fully understood. The process of muscle damage following unaccustomed eccentric exercise 
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and recovery can be summarized as 1) initial mechanical injury, 2) muscle damage, 3) 
inflammatory response, 4) neutrophil release of oxygen free radicals and lysosomal proteases, 
which can lead to additional muscle damage and 5) eventual regeneration and repair (Toumi 
& Best, 2003). Muscle damage “involves a variety of histopathological changes, including 
swelling of muscle cells, loss of the intermediate filament proteins desmin and dystrophin, 
and inflammatory cell infiltration” (Toumi & Best, 2003). Data from previous studies has 
demonstrated that cytoskeletal disruption occurs early during exercise designed to cause 
EIMD in a rabbit model (Lieber, Thornell, & Fridén, 1996).  
The first stage of EIMD is the initial or initiating event. The ‘popping sarcomere 
hypothesis’ describes the mechanical injury event as a lengthening of sarcomeres beyond their 
functional limit. The likelihood of cross-bridge formation decreases under conditions of 
increasing muscle length while generating tension. Sarcomeres can be stretched to the point at 
which passive tension is able to provide the required tension. Upon relaxation, some 
sarcomeres are able to reinterdigitate and resume normal force production while others are 
disrupted and unable to generate further active tension (Morgan & Allen, 1999). 
Unaccustomed eccentric exercise has been used in human models as the initiating event in 
many studies. Initial signs of muscle damage from the initiating event include “a) disruption 
of the normal myofilament structures in some sarcomeres, observable with both light and 
electron microscope and b) loss of intramuscular proteins (e.g., creatine kinase enzymes) into 
the plasma, indicating damage to sarcolemma” (Armstrong, 1990).  
While the presence of disrupted sarcomeres and damage to the excitation-contraction 
coupling system are both prominent early signs of muscle damage, there has been debate on 
which is the primary event. Proske and Morgan (2001) argue that the damage process is 
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initiated by overstretch of the sarcomeres. Warren el al. (2001), however argue that most of 
the decline in muscle force capability can be attributed to the excitation-contraction couple 
dysfunction, which is also known as excitation-contraction uncoupling. Lending support to 
the latter argument is evidence that caffeine injection into the muscle following fatigue can 
restore force production capability in mice (Warren et al., 1993). 
The second stage of muscle damage is termed the autogenetic stage and is described as 
“the period immediately following the initiating event when proteolytic and lipolytic systems 
indigenous to the muscle fibers begin the process of degrading cellular structures” 
(Armstrong, 1990). Exercise may cause disruption of the sarcolemma, increasing cell 
membrane permeability and allowing intramuscular proteins such as creatine kinase and 
lactate dehydrogenase to be released to the extracellular space. Concomitantly, increased 
permeability of the cell membrane allows Ca2+ and other concentrated extracellular molecules 
to enter the cell at higher than normal concentrations. Increased [Ca2+] is a common factor in 
a number of potential autogenetic mechanisms in muscle cell injury (Figure 2), including 
being a precursor for phospholipase A2 (PLA2) activation. PLA2 activation which leads to 
increased cell membrane permeability and release of arachidonic acid, initiating an 
inflammatory response to the muscle damage (Gissel, 2005).  
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Figure 2: Autogenetic Mechanisms in Muscle Cell Following Exercise-Induced Injury (Armstrong, 1990) 
 
The phagocytic stage, or inflammatory response, “is prevalent from 4-6 h after the 
initiating event through 2-4 d following exercise and is marked by a typical inflammatory 
response in the tissue” (Armstrong, 1990). The inflammatory response to eccentric exercise 
injury is characterized by neutrophilia, neutrophil activation, and the accumulation of 
neutrophils within the injured muscle as early as one to two hours after muscle damage 
(Fielding et al., 1993). Neutrophils are capable of releasing arachidonic acid, which can be 
metabolized through the cyclooxygenase pathway into pro-inflammatory prostaglandins 
(Walsh, Waite, Thomas, & DeChatelet, 1981) or by the 5-lipoxygenase pathway into 
leukotrienes (Mickleborough & Rundell, 2005). Connolly et al. (2003) provide a simple 
schematic (Figure 1) of the processes leading to inflammation influenced muscle damage 
following exercise. Following damage to the muscle cell membrane PLA2 is activated, which 
leads to prostaglandin and leukotriene production. 
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Figure 3: Schematic showing possible sequence of injury due to inflammatory processes following an exercise-
induced muscle damage initiating event 
 
Reactive oxygen species (ROS) are an emerging focus in EIMD and DOMS research 
(Close, Ashton, McArdle, & Maclaren, 2005). ROS are oxygen-centered molecules with an 
unpaired electron, which makes them highly reactive as the unpaired electron is unstable. 
ROS are generated by normal metabolic processes and the rate of generation is elevated 
during exercise. A ROS may pair with either another ROS, which is termed a termination 
reaction, and no further reactions occur for the two involved ROS. However, if a ROS pairs 
with a non-ROS, then a new ROS is formed which remains highly reactive. Continuing 
reactions may occur, which in the case of skeletal muscle membranes, can lead to damage to 
cell membrane phospholipids and compromise the integrity of the cell membrane itself (Close 
et al., 2005). 
In the case of EIMD, the involvement of ROS in the damage and repair process is 
related to the inflammatory processes that occur following the initial damaging event. During 
and following eccentric muscle contractions, monocytes/macrophages, eosinophils and 
neutrophils are activated (Malm, Lenkei, & Sjödin, 1999) and produce ROS to attack 
damaged muscle cells (Close et al., 2005). In mouse models, the secondary damaging event 
has been shown to occur at three days post-exercise, is associated with an elevated ROS level 
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(A McArdle et al., 1999) and force loss attributed to ROS can be attenuated by treatment with 
polyethylene glycol-superoxide dismutase, a free radical scavenger (Zerba, Komorowski, & 
Faulkner, 1990). 
There remains some debate as to whether inflammation resulting from EIMD is an 
overall positive or negative response in terms of muscle recovery and adaptation to the 
exercise stimulus. Toumi and Best (2003) describe the view as the thought that “the events 
following the initial injury, including inflammation, are necessary for optimal repair.”  
However, neutrophil invasion of the damage site and neutrophil activation has the potential to 
release a number of damaging molecules into the muscle, including “40 hydrolytic enzymes 
and toxic molecules in their granules and [neutrophils] can generate various oxidants such as 
superoxide anion, hydrogen peroxide, and hypochlorous acid.” Brickson et al. (2003) found 
that blocking the CD11b-dependent respiratory burst in stretch-injured rabbits with 
monoclonal antibody M1/70 resulted in less myofiber damage following the injury. 
In addition to their potential contribution to secondary damage seen following 
eccentric exercise, production of ROS following muscle damage may be a necessary 
component of the recovery and adaptation, acting as a signaling component for regenerative 
processes (Anne McArdle, Vasilaki, & Jackson, 2002). Following cellular stress, heat shock 
protein (HSP) levels are elevated, which is hypothesized to provide protection against further 
stress and to facilitate recovery and remodeling (Hernando & Manso, 1997). Anti-oxidant 
supplementation attenuates the increase of HSP content in the muscle following stress 
(Khassaf et al., 2001). Thus, it appears that there may be a balance between the cell damaging 
effects of ROS production and the adaptive responses activated by ROS production.  
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Muscle Damage Exercise Models 
A number of different protocols have been used in the literature to produce exercise-
induced muscle damage. For endurance-related EIMD research, downhill running is a 
common method of inducing muscle damage. Studies have used varying running speeds, 
durations and treadmill inclines during downhill running to produce EIMD (Table 1) (Tiidus, 
2008). 
Other researchers have used downhill running intensities based on relative percentage 
of max HR (Shave, Dawson, & Whyte, 2002), a chosen treadmill speed (Koller et al., 1998), a 
chosen heart rate (Byrnes et al., 1985) and subject preference while running down stairs (Yu, 
Malm, & Thornell, 2002). Eston et al. (1996) used a protocol consisting of five bouts of 8 
minutes running at 80% of predicted max HR on a treadmill set at -10° incline. The same 
protocol was used by Pumpa et al. (2011).  
Table 1: Downhill Running Exercise Protocols 
Study Running Speed Duration (min) Incline 
(Sorichter et al., 1997) 70% V̇O2max 20 -16% 
(Shave et al., 2002) 70% max running 
velocity 
30 -15% 
(Koller et al., 1998) 9 km/hr 25 -25% 
(Byrnes et al., 1985) 170 bpm HR 60 -10% 
(Yu et al., 2002) Subject preference 45 Unknown 
(R G Eston et al., 1996) 80% predicted 
HRmax 
5 x 8 min, 2 min 
rest between bouts 
-10% 
(Pumpa et al., 2011) 80% predicted 
HRmax 
5 x 8 min, 2 min 
rest between bouts 
-10% 
 
Sorichter et al. (1997) used downhill running at 70% of VO2max at a gradient of -16% 
for 20 min to induce muscle damage for the purposes of measuring the appearance of skeletal 
troponin I (sTnI) in plasma. This protocol was successful in producing the appearance of sTnI 
in blood plasma at elevated levels compared to those seen during a similar run on a level 
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treadmill (Figure 4). Subsequent research has supported the finding of elevated levels of sTnI 
in blood plasma following eccentric exercise (Chapman, Simpson, Iscoe, Robins, & Nosaka, 
2013; Willoughby, 2003). 
 
Figure 4: Time course of sTnI, Mb, CK and MHC following downhill running at -16% for 20 minutes at 70% of 
V̇O2max (Sorichter et al., 1997)  
 
Troponin is a three subunit protein complex involved in the regulation of muscle cell 
contraction. Troponin C (TnC) is the subunit that binds to calcium. Troponin I (TnI) is a 
central subunit, binding to actin, TnC and troponin T (TnT). TnT binds the troponin complex 
to tropomyosin. Figure 5 depicts the troponin complex in conjunction with actin and 
tropomyosin. Contraction regulation occurs through the interaction of Ca2+-dependent 
interaction of TnC and TnI. Ca2+ binding to TnC increases the affinity of TnC-TnI, switching 
TnI from binding at multiple sites on actin to sites on TnC. This configurational change pulls 
tropomyosin away from actin, exposing the active sites on actin which enables myosin to 
form cross bridges with actin (Gordon, Homsher, & Regnier, 2000; Plowman & Smith, 2011). 
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Figure 5: Troponin complex as part of muscle fiber thin filament (Gordon et al., 2000) 
 
Only a few studies have investigated cycling performance following eccentric exercise 
or eccentric cycling exercise itself. Vertical jumping protocols, squatting, bench stepping and 
using modified cycle ergometers that require the subject to resist backward motor-driven 
movement of the pedals have been used (Table 2). 
Table 2: Exercise Protocols Used in Cycling EIMD Studies 
Study Protocol 
(Twist & Eston, 2009) 100 counter-movement vertical jumps 
(Moysi et al., 2005) 25 reps of squats with 150% body mass load every 10 minutes 
during cycling 
(Gleeson, Blannin, Zhu, 
Brooks, & Cave, 1995) 
30 min of bench stepping (47-cm step, 15 steps min-1) 
(Cannon & Fiatarone, 1994) Resisting bicycle pedals driven backward by a motor for 45 
min (3 x 15 min bouts) at an intensity of 78 ± 6% of HRmax 
(Yu et al., 2002) Resisting bicycle pedals driven backward by a motor for 30 
min at or near concentric V̇O2max (250 or 300W) 
(O’Reilly et al., 1987) 3 x 15 min at 90, 80 and 70 % V̇O2max on eccentric cycle 
ergometer 
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EIMD and Exercise Performance  
EIMD has been shown to impair muscle strength and endurance exercise performance. 
One of the most tested and consistent findings in EIMD research is loss of strength 
immediately following exercise (Tiidus, 2008), with estimates of 50% of human EIMD 
studies reporting maximal voluntary contraction (Warren, Lowe, & Armstrong, 1999).  
Typically, eccentric resistance exercise produces an immediate loss in force production 
capability that recovers over the days and weeks following the exercise bout (Figure 6) 
(Balnave & Thompson, 1993; Clarkson, Nosaka, & Braun, 1992). 
 
Figure 6: Typical Force Decrement in Forearm Flexor Muscles Following Eccentric Exercise (Clarkson et al., 
1992) 
 
There are numerous examples in the literature of decrements in strength and force 
production due to EIMD, a few of which are reviewed here. Davies and White (1981) found 
that muscle force production is reduced following eccentric exercise, which they 
demonstrated with direct electrical stimulation. EIMD brought about by 100 barbell squats 
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reduced muscle strength during isometric, eccentric and concentric contractions for 4 days 
and vertical jump performance. Also, plasma CK values were elevated for 3 days following 
the exercise bout (Byrne & Eston, 2002b). Balnave and Thompson (1993) reported a 17% 
decline in quadriceps MVC following a 40 minute downhill walk by nine healthy, sedentary 
subjects. Clarkson et al. (1992) found 50% decrements in MVC of the forearm flexor muscles 
following two sets of 35 maximal contractions, compiled from the pooled data from control 
subjects in several of their studies. Decreased strength was still evident at 10 days following 
the initial exercise bout (Figure 6). 
Submaximal endurance exercise performance is affected by a previous bout of 
exercise that causes EIMD (Burt, Lamb, Nicholas, & Twist, 2012). While this study did not 
include a performance measure, the authors did report that ventilation was increased during 
both running and cycling and they postulated that additional recruitment of secondary muscles 
may have contributed to the difference. Running economy was found to decrease following 
EIMD in a group of well-trained runners and triathletes, a finding that may be due to altered 
motor unit recruitment patterns (Braun & Dutto, 2003). Marcora and Bosio (2007) found that 
self-paced running time trial performance was reduced by 4% (p < .01) following eccentric 
exercise compared to baseline without significant changes in perceived exertion. Davies et al. 
(2009) investigated cycling performance following squat exercise and found reduced time-to-
exhaustion during severe exercise.  
Doncaster and Twist (2012) found that time-to-exhaustion in arm cranking exercise 
was reduced following bench press exercise. Nine physically active men were asked to 
performance ten sets of six bench presses using a weight of 70% of their one repetition 
maximum (1-RM). Focus was given to the eccentric portion of the exercise, which was 
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completed in 3 seconds for each repetition, while the concentric portion of each repetition was 
completed in 1 second. Time to exhaustion for arm cranking occurred at an intensity equal to 
80% between ventilatory threshold and V̇O2peak, an intensity within the severe exercise 
domain. Time to exhaustion in the treatment group (207.2 ± 91.9 s) was significantly (p < .05) 
lower than the control group (293.4 ± 75.6 s). 
Eccentric exercise has previously been found to cause decrements in cycling 
performance. In seven recreationally trained men (Twist & Eston, 2009), EIMD was induced 
by 100 counter-movement jumps and the performance test consisted of a 5 minute time trial 
on a cycle ergometer. Mean power output and worked performed during the time trial 
decreased from baseline (262.8 ± 17.7 W) at 48 hours (232.8 ± 15.3 W, p < .05) and had 
returned to baseline by 168 hours (266.1 ± 15.3 W, p > .05). RPE was increased at 60% 
(baseline: 13.7 ± 0.4, 48 h: 15.4 ± 0.7, p < 0.05) and 80% (baseline: 17.7 ± 0.5, 48 h: 18.3 ± 
0.7, p < 0.05) of power at V̇O2max during steady state cycling following EIMD. This study was 
the first to look at an “ecologically valid measure of cycling performance” in relation to 
EIMD and DOMS (Twist & Eston, 2009). 
EIMD reduces V̇O2peak and ventilatory threshold during cycling, two parameters that 
are associated with exercise performance (Black & Dobson, 2012). In a study of eleven 
recreationally active college students (5 men, 6 women), V̇O2peak decreased from 46.2 ± 9.7 
ml/kg/min to 41.8 ± 10.7 ml/kg/min (p = .01) and ventilatory threshold decreased from 34.2 ± 
7.8 to 30.5 ± 8.5 ml/kg/min (p = .031). Muscle damage was induced by 3 sets of 8 single-leg 
knee contractions, completed on both legs, with the load initially set to 120% of 1-RM. 
Subjects lowered the weight from level to 90º over three seconds. When the load could not be 
lowered in a controlled manner, the weight was decreased by 5% and the set continued. 
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Additional studies have noted decrements in cycling performance following EIMD. 
Byrne and Eston (2002a) found significant (p < .05) decrements in Wingate cycling test 
results 1 hour, 1, 2, 3 and 7 days after an exercise bout of 10 sets of 10 repetitions of the 
eccentric portion of a barbell squat with a load of 80% of 1-RM. Sargeant and Dolan (1987) 
observed decreased anaerobic power output on a cycle ergometer following downhill walking 
at 6.44 km/hr at a -25% gradient. In this study, short term maximal power output (20 sec) on a 
cycle ergometer was reduced from baseline to 77 ± 10% (p < 0.05) at 24 h post exercise with 
performance decrements persisting through 96 h (92 ± 4%; p < 0.05). 
However, some studies have not found changes in exercise performance following 
eccentric exercise. In a group of trained rugby and field hockey players, sprinting 
performance was not affected by a previous eccentric exercise bout of seven sets of 10 drop 
jumps. Sprinting performance was measured with a 30 meter sprint before exercise and at 12, 
24, 48 and 72 hours. One limitation of this study is that there was no significant differences 
creatine kinase over time, which may indicate that the exercise protocol was not strenuous 
enough to produce significant damage (Semark, Noakes, St Clair Gibson, & Lambert, 1999). 
Gleeson et al. (1998) did not observe a significant change in time to exhaustion during cycling 
after 40 minutes of bench stepping exercise. The time to exhaustion measure was the time to 
completion of a V̇O2peak test. V̇O2peak was also not changed as a result of the exercise bout. 
One phenomenon that affects the design of EIMD research protocols is known as the 
repeated-bout effect. The repeated-bout effect describes the tendency of EIMD and DOMS to 
be reduced in the weeks and months following an initial damaging exercise bout. Cleary et al. 
(2002) determined that the repeated bout effect lasts as long as nine weeks following the 
initial exercise bout, although further time points were not measured in this study. In a study 
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designed to test whether stride length affects symptoms of EIMD, no significant differences 
were found among stride lengths but the authors did note that symptoms of EIMD were 
lessened in the second trial where stride length was altered (R. G. Eston, Lemmey, McHugh, 
Byrne, & Walsh, 2000). Due to the repeated-bout effect, EIMD studies usually do not feature 
a cross-over design because subjects would not be expected to respond to an exercise bout in 
the same manner multiple times without lengthy delays between trials. 
Delayed Onset Muscle Soreness 
Delayed onset muscle soreness (DOMS), the feeling of pain and soreness that follows 
a bout of intensive or unaccustomed exercise, is a sensation familiar to most who have 
participated in sport and exercise. The symptoms and hypothesized causes of delayed onset 
muscle soreness were first described at the turn of the 20th century (Hough, 1902). Hough 
(1902) established in early EIMD/DOMS research that muscular performance can be reduced 
in the presence of DOMS. His findings suggest that performance is affected both by a 
reduction in voluntary effort and a reduction in the ability of the muscle to produce force.  
The mechanisms underlying DOMS have been a topic of debate in the literature. 
Several hypotheses have been proposed to explain the cause of DOMS including lactic acid, 
muscle spasm, connection tissue damage, muscle damage, inflammation and enzyme efflux 
theory (Cheung et al., 2003). The current consensus is that these factors may each contribute 
to DOMS to some degree (Armstrong, 1984; Lewis et al., 2012). 
DOMS may potentially affect any skeletal muscle that has been exercised to a 
sufficient extent, generally in exercises utilizing eccentric contractions. DOMS is generally 
localized in the distal portion of the muscle, typically near the muscle-tendon junction 
(Armstrong, 1984). The proposed causes for sensitivity localization are varied and include 
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increased concentration of pain receptors in this area (Kumazawa & Mizumura, 1977) or a 
higher incidence of muscle damage in specific portions of the muscle (Newham, Mills, 
Quigley, & Edwards, 1982). During severe DOMS results in pain that is not localized, but 
rather spread throughout the muscle (Newham, Mills, Quigley, & Edwards, 1983). 
Eccentric contractions are usually used in research models to induce symptoms of 
DOMS in research subjects (Tiidus, 2008). Among the three types of contractions (eccentric, 
concentric and isometric), eccentric contractions produce the most tension on muscle and 
connective tissues (Lieber & Friden, 2002). Asmussen (1956) first established that DOMS is 
primarily associated with eccentric contractions. 
Although many studies have measured DOMS and use it as an indirect indicator of 
EIMD, it is not clear that DOMS and EIMD are always correlated. Nosaka et al. (2002) found 
that DOMS did not increase in accordance with EIMD measured by other indirect markers, 
such as muscle strength. Additionally, the sensation of pain is individual, difficult to quantify 
and different subjects may interpret any given pain scale differently. The authors concluded 
that “it should be noted that preventative or treatment measures for DOMS are not necessarily 
the same as those for muscle degeneration and regeneration.” 
A number of studies have investigated different treatments for DOMS that may reduce 
pain and performance decrements in the days following muscle damaging exercise including 
“cryotherapy, stretching, anti-inflammatory drugs, ultrasound, electrical current techniques, 
homeopathy, massage, compression, hyperbaric oxygen and exercise” (Cheung et al., 2003). 
In general, results have been equivocal and there is no consensus regarding the efficacy of 
treatments for EIMD and DOMS (Cheung et al., 2003).  
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Non-steroidal anti-inflammatory drugs (NSAIDs) which are commonly used by 
athletes to prevent and treat soreness, have been an area of interest in EIMD and DOMS 
research. (Paoloni, Milne, Orchard, & Hamilton, 2009). Some success in the treatment of 
DOMS has been seen with non-steroidal anti-inflammatory (NSAID) use, and NSAIDs are 
commonly recommended by doctors and used by athletes for the purpose of treating exercise-
related muscle and joint pain (Paoloni et al., 2009).  
Naproxen sodium (commonly sold as Aleve) improved strength recovery, lessened 
swelling measured by cross-sectional area and improve sleep and morning activities compared 
to placebo (Dudley et al., 1997).  Like PCSO-524™, NSAIDs act to inhibit “the enzyme 
cyclo-oxygenase and thereby decreas[e] the production of prostaglandins which are capable of 
mediating the inflammatory response following injury” (Almekinders, 1999). 
However, not all studies have found positive effects from NSAID treatment. Gulick et 
al. (1996) investigated a number of treatments including “a nonsteroidal anti-inflammatory 
drug, high velocity concentric muscle contractions on an upper extremity ergometer, ice 
massage, 10-minute static stretching, topical Arnica montana ointment, and sublingual A. 
montana pellets.” None of the treatments were effective in reducing DOMS and “the NSAID 
and A. montana treatments appeared to impede recovery of muscle function” (Gulick et al., 
1996). Similarly, ibuprofen did not affect muscle soreness or reduce decrements in endurance 
performance following downhill running (Donnelly et al., 1990). 
Some success has been found in other treatments for symptoms of EIMD. Phillips et 
al. (2003) saw reduced interleukin-6 (IL-6) and C-reactive protein, two proteins involved in 
the acute inflammatory response, in subjects taking a supplement containing tocopherols, 
flavonoids, and docosahexaenoate. Specialized clothing has also been hypothesized to reduce 
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DOMS symptoms. Zhang et al. (2000) found significant differences in pain, strength and 
several blood markers of muscle damage in response to a treatment involving an 
electromagnetic shielding fabric. A meta-analysis 12 studies that evaluated the effectiveness 
of compression garmets concluded that such clothing has a moderate effect on the severity of 
DOMS resulting from eccentric exercise (J. Hill, Howatson, van Someren, Leeder, & Pedlar, 
2013).  
Peripheral Muscle Fatigue 
Fatigue is a “reversible decline in force production by muscles when contracting at or 
near their maximum capacity” (Bishop, 2012), where the ability of the muscle to perform 
work, maintain force or produce power is compromised (Asmussen, 1979; Bigland-Ritchie, 
Johansson, Lippold, & Woods, 1983). The decline in capacity may be identified by reduced 
power output during cycling, reduced speed during running or reduced ability to produce 
force during lifting exercises, for example. 
The contributing factors to fatigue have been generally categorized as peripheral 
factors or central factors. The classic model of fatigue describes conditions in the periphery 
that inhibit the contractile function of muscle. Cellular changes that contribute to fatigue may 
include accumulation of inorganic phosphate, impaired calcium reuptake, acidosis, reduced 
glycogen availability and the production of reactive oxygen species in muscle tissue (Allen, 
Lamb, & Westerblad, 2008). Slowed cross bridge attachment may also be a molecular factor 
in fatigue (Jones, Turner, McIntyre, & Newham, 2009). Central nervous system factors 
contribute to fatigue during exercise. A reduction in central nervous system efferent output 
has been observed following strenuous exercise (Brasil-Neto, Cohen, & Hallett, 1994). 
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An integrated model of fatigue, the Central Governor Model, describes fatigue as a 
mechanism to protect whole-body homeostasis during exercise and the sensation of fatigue as 
an emotion reflecting sensory input from the periphery (Noakes, 2012). The reduction in 
power output during prolonged cycling exercise, for example, may be a result of a number of 
integrated factors including motivation, self-belief, pacing strategy, previous experience, 
environmental conditions and afferent feedback from the periphery (Noakes, 2011). 
In order to isolate peripheral, central and integrated fatigue factors in muscle fatigue, 
techniques have been developed to study muscle function in vivo by way of stimulating 
efferent nerves, usually using surface electrodes, implanted electrodes or magnetic 
stimulation. Through bypassing the central nervous system, an “effort independent measure of 
muscle contractile performance” may be obtained (Kufel, Pineda, & Mador, 2002; Polkey et 
al., 1996). 
Muscle contractile function is affected by the recent contraction history of the muscle 
fiber. Twitch force is either measured as potentiated or unpotentiated contractions. Potentiated 
twitches are those that are induced after recent maximal voluntary contraction or tetanic 
stimulation, while unpotentiated twitches are performed on a rested, not recently contracted 
muscle (Kufel et al., 2002). Fatigue can be detected in the quadriceps muscle effectively using 
a potentiated twitch model more effective than with unpotentiated twitches (Kufel et al., 2002; 
Polkey et al., 1996). Kufel et al. (2002) investigated both potentiated (Qtw,pot) and 
unpotentiated (Qtw,unpot) following 10, 15, 20 and 30 MVC maneuvers of 5 seconds each. 
Qtw,pot fell by as much as about 40% after 30 MVC maneuvers. Polkey et al. (1996) showed 
that quadriceps fatigue can be detected using a magnetic stimulator following a protocol in 
which subjects maintain contractions at 60% of MVC for as long as possible. 
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ω3FA supplementation may be related to improved muscle fatigue resistance during 
exercise and metabolic stress. Pepe and McLennan (2002) investigated the effects of ω3FA 
supplementation on oxygen consumption and recovery from ischemic stress in cardiac 
muscles. Male Wistar rats were supplemented with diets containing increased ω3FA content 
(45% PUFA; 39% EPA and DHA), saturated fat (55% saturated fat) or a reference diet (46% 
PUFA; 34% n-6 PUFA) for 16 weeks. The researchers found that ω3FA supplemented rats had 
a myocardial oxygen consumption and were able to recover from ischemic stress more readily 
than rats on the alternative diets.  
Peoples et al. (2013) showed ω3FA supplementation reduces skeletal muscle fatigue in 
a rat model during sustained electrically stimulated contractions. The diets of Wistar rats were 
manipulated to contain fat primarily from either saturated, n-3 or n-6 unsaturated fats. The n-3 
group primarily consumed DHA. During 30 minutes of sustained isolated electrically 
stimulated hindlimb contractions, n-3 consuming rats developed greater maximum twitch 
tension, maintain higher peak twitch tension throughout compared to the saturated and n-6 
groups. The n-3 group had attenuated changes in twitch development and faster twitch 
development, relaxation rates, shorter rise and fall time and twitch duration. Potential 
mechanisms for the differences seen in this study may include protection of the Ca2+ cycling 
process and an attenuated impairment of Ca2+ removal from the sarcoplasmic reticulum 
(Peoples & McLennan, 2013). 
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CHAPTER 3 
METHODS 
Subjects 
Forty untrained men ages 18-26 were recruited from the surrounding Bloomington 
area to participate in the investigation. Thirty-four subjects completed the study. The reasons 
for subjects leaving the study were difficulty with venous blood draw (3 subjects), family 
emergency (1 subject), job conflict (1 subject), and not returning to the laboratory following 
supplementation (1 subject). Data from two subjects were discarded, initially based on 
inspection of DOMS data indicating implausible values or measurement error. Women were 
not recruited to this study as it is unclear whether the menstrual cycle and associated 
hormones affect markers of EIMD (Clarkson & Hubal, 2002). 
Subjects were classified as ‘untrained’ if they exercised less than three times per week 
for less than 30 minutes during each session. Subjects were excluded if they had a history of 
significant pain in hips or knees, had participated in a strength training program with 60 days 
prior to their screening for the study, or regularly used anti-inflammatory medication or 
nutritional supplements. Subjects were screened for risks factors per American College of 
Sports Medicine guidelines for age, body mass index, blood pressure, cholesterol, and fasting 
blood glucose. Subjects were excluded from the study if they did not meet the conditions 
outlined in Table 3. 
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Table 3: Study screening criteria for exercise risk factors 
 Criteria  
Age Subjects were accepted only if they were between 18 and 30 
years of age. 
Body Mass Index Subjects were accepted only if they have a BMI < 30. 
Blood Pressure Subjects were accepted only if their blood pressure was less 
than 140/90 mmHg. 
Cholesterol Subjects were accepted only if their total cholesterol count 
was less than 200 mg/dL. 
Fasting Blood Glucose Subjects were accepted only if their fasting blood glucose 
was less than 100 mg/dL. 
 
Untrained subjects were chosen for this study (as opposed to trained, well-trained or 
elite athletes) on the basis of data from previous research investigating eccentric exercise, 
EIMD/DOMS and PCSO-524™ supplementation that showed no effects among trained 
subjects (Pumpa et al., 2011) or greater effects among less-trained subjects (Baum et al., 
2013). Pumpa et al. (2011) included well-trained men participating in sports including 
“Australian Football, cycling, middle and long distance running and rugby union”. Data from 
this study showed no differences in several measures of muscle damage and soreness between 
PCSO-524™ supplementation and placebo. Baum et al. (2013) noted greater differences in 
muscle soreness between PCSO-524™ supplementation and placebo groups among less-
trained runners after a 30km run. Based on these results, the present study included untrained 
subjects as training status appears to play a role in the efficacy of PCSO-524™ 
supplementation to treat EIMD/DOMS. 
Subjects were instructed to refrain from downhill running, stair running, resistance 
training, plyometric or other exercise that could cause muscle damage during the study. 
Subjects were instructed to refrain from using anti-inflammatory medication or nutritional 
supplements during the study. Subjects were instructed to refrain from increasing or 
modifying their exercise habits during the course of the study. Adherence to these instructions 
 
  
44 
 
was confirmed at each visit to the laboratory. The study was approved by the Indiana 
University Human Research Protection Program Committee (HRPP). All subjects gave their 
written informed consent to participate in the study as approved by the HRPP. 
Study Design  
A schematic of study procedures is presented below (Figure 7). Subjects were 
randomly assigned to either a PCSO-524™ supplementation group receiving 8 capsules of 
PCSO-524™ (800 mg olive oil, 400 mg lipid extract) (n=16) or a placebo group receiving 8 
capsules containing olive oil (1200 mg olive oil) (n=16) for 30 days. A non-involved 
researcher prepared supplement bags to ensure both investigators and subjects were blinded. 
A non-crossover design was chosen for this study to avoid the “repeated-bout effect” 
as a confounding variable. The repeated-bout effect describes protective effect of an initial 
damaging exercise bout on EIMD and DOMS during a subsequent exercise bout in the weeks 
and months following (Tiidus, 2008, pp. 69–70). Cleary et al. (2002) determined that the 
repeated bout effect lasts as long as nine weeks following the initial exercise bout. Other data 
has shown that the repeated bout effect can last as long as six months (Tiidus, 2008, p. 70). 
Due to the repeated-bout effect, EIMD studies usually do not use a crossover design because 
subjects would not be expected to respond to an exercise bout in the same manner multiple 
times without lengthy delays between trials.  
Prior to the supplementation period, baseline measurements for peak aerobic exercise 
capacity (VO2max), 20 minute cycle ergometer time trial performance, quadriceps muscle 
fatigue following the time trial, skeletal troponin I and quadriceps soreness were taken. Each 
subject completed a screening and familiarization session, a VO2max testing session and 
exercise performance testing on different days. 
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After 26 days of supplementation, post-supplementation measures of skeletal troponin 
I and quadriceps soreness were taken. On the same day, subjects performed downhill running 
at -16% incline for 20 minutes at 70% of heart rate reserve (HRR), an eccentric exercise bout 
intended to produce muscle damage and peripheral muscle fatigue and modeled after the 
protocol used by Sorichter et al. (1997). Running speed was heart rate monitored. The target 
heart rate was 70% HRR, which was determined in the VO2max test from resting and 
maximum heart rate. The downhill running protocol was performed on a treadmill (A. R. 
Young Power Transmission Engineers, Indianapolis, IN) that was adapted to allow the belt to 
run in reverse. Skeletal troponin I was evaluated at immediately following, two hours, 24 
hours, 48 hours, 72 hours and 96 hours following the downhill running protocol. Perceived 
soreness/pain (DOMS) was evaluated at 24 hours, 48 hours, 72 hours and 96 hours following 
the downhill running protocol. 
Twenty-four hours following the eccentric exercise bout, subjects performed a 20 
minute cycle ergometer time trial. Quadriceps muscle fatigue was measured following the 
time trial. The timing for the time trial was chosen to correspond with expected peaks in 
strength loss, fatigue, range of motion and beginning of significant soreness (Tiidus, 2008), 
and thus have a potential effect on performance. 
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Figure 7:  Schematic of Study Procedures. Procedures/Measurements in Light Grey were collected by another 
investigator during the same study. Muscle damage indicators include range of motion (ROM), thigh 
circumference and pressure sensitivity. Additional blood markers include heart-type fatty acid binding protein (h-
FABP), myoglobin (MB), creatine kinase (CK), 8-hydroxydeoxyguanosine (8-OHdG), tumor necrosis factor 
(TNF-α) and interleukin-6 (IL-6). 
Measurements 
Maximal Aerobic Exercise Capacity (V̇O2max) 
Subjects performed a maximal aerobic exercise capacity test on a motor driven 
treadmill (Model 18-60, Quinton, Seattle, WA). Subjects were briefed on the procedures of 
the test and safety precautions prior to beginning the test. A warm-up period of 5 minutes was 
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used to determine a running speed for each subject. After fitting the subject with a heart rate 
monitor (Polar Electro Inc., Lake Success, NY) and breathing mask (7450 Series V2, Hans 
Rudolph, Shawnee, KS USA), the test began with 5 minutes of seated rest while equipment 
function was verified and baseline metabolic measurements were collected. 
The exercise portion of the test began with each subject running at 0% grade and a 
speed of 1.6 k/h less than the selected speed for 2 minutes. Following the initial stage, the 
speed was increased to the predetermined speed for 3 minutes. Then, the slope of the treadmill 
was increased to 4% for 3 minutes, and increased an additional 2% every 3 minutes until 
volitional exhaustion or valid test criteria were met (see below). Subjects were asked at the 
end of each minute if they could continue the test. 
Tests were considered valid if they met two of the following criteria: 1) reaching a 
heart rate ≥ 90% of the predicted maximum heart rate (220 - age), 2) a respiratory exchange 
ratio (RER) ≥ 1.10, and 3) ≤ 150 mL increase in V̇O2 with an increase in treadmill slope. 
Ventilatory and metabolic data were collected using open-circuit, indirect calorimetry. 
Dried expired gases were sampled at a rate of 300 mL/min for fractional concentrations of O2 
and CO2 using an Applied Electrochemistry S-3A oxygen analyzer and a CD-3A carbon 
dioxide analyzer (Ametek, Thermox Instruments, Pittsburgh, PA). Inspired ventilation was 
measured with a pneumotachometer (Hans Rudolph 3813). V̇E was calculated using the 
Haldane Transformation. 
Twenty Minute Cycle Ergometer Time Trial 
All subjects completed three 20 minute time trials on an electronically braked cycle ergometer 
(Velotron, RacerMate Inc., Seattle, Washington, USA). The first time trial was used for 
familiarization purposes. The second time trial occurred prior to supplementation. The third 
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time trial occurred after 26 days of supplementation and 24 hours following the downhill 
running protocol. Average power output was assessed at each 5 minute interval to assess 
performance. Heart rate (Polar, Polar Electro Oy, Kempele, Finland), power output, and rating 
of perceived exertion were recorded. The timing for the time trial was chosen to correspond 
with expected peaks in strength loss, fatigue, range of motion and beginning of significant 
soreness after eccentric exercise (Tiidus, 2008), and thus have a potential effect on 
performance. 
Subjects were informed that the goal of the time trial was to achieve the highest 
possible average power output. Subjects were informed of their progress via a computer 
program (CompuTrainer 3D, RacerMate Inc., Seattle, Washington, USA) on a display that 
displayed elapsed time, current power output, average power output, heart rate and a 
simulated bicycle gear indicator. The cycle ergometer was adjusted for each subject’s seat and 
handle height preferences prior to the initial time trial. Adjustments for cycling position were 
recorded for each subject and repeated for subsequent time trials. A continuously running fan 
was placed near the bicycle to provide a degree of air flow and cooling. 
Potentiated Quadriceps Twitch Force 
Quadriceps muscles are employed during cycling for a substantial portion of the pedal 
stroke (Jorge & Hull, 1986). During prolonged or high-intensity cycling, decrements in the 
force generating capability of the quadriceps muscles are observed (Lepers, Maffiuletti, 
Rochette, Brugniaux, & Millet, 2002). One of the methods that has been used to demonstrate 
non-volitional neuromuscular fatigue following cycling is measurement of quadriceps twitch 
force (Lepers et al., 2002). 
In the present study, potentiated quadriceps twitch force was measured in the subject’s 
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left leg to quantify an index of muscle fatigue following the cycle ergometer time trial. 
Muscle twitch force is typically measured in either a potentiated or unpotentiated state. 
Potentiated twitches are those that are induced after recent maximal voluntary contraction or 
tetanic stimulation, while unpotentiated twitches are performed while the subject has been at 
rest (Kufel et al., 2002). Fatigue of the quadriceps muscles is more reliably and easily 
detectable when a potentiated twitch is measured, as opposed to an unpotentiated twitch 
(Kufel et al., 2002). 
The subject was supine on a table with a left knee joint angle of 90 degrees. The 
subject’s ankle was wrapped in a non-compliant strap, placed just superior to the ankle 
malleoli. The strap was attached to a calibrated load cell (Model Z Tension Load Cell, Dillon, 
Fairmont, MN) for the measurement of force connected to a custom amplifier (Hector 
Engineering Co. Inc., Ellettsville, IN). A magnetic stimulator (Magstim 200, Magstim, 
Whitland, UK) connected to a double 70 mm coil was used to stimulate the femoral nerve, 
causing an involuntary contraction of the quadriceps muscle. 
Nerve stimulation followed two protocols, following a protocol described previously 
(Amann et al., 2007; Kufel et al., 2002; Polkey et al., 1996): 
Assessment of maximal nerve stimulation 
Prior to the cycle ergometer time trial, a series of single twitches were obtained at 
varying levels of stimulator intensity (80%, 85%, 90%, 95%, and 100% of maximal stimulator 
power output) to determine when supramaximal stimulation had been reached. The position of 
the stimulator coil was placed over the femoral triangle and adjusted to determine an 
acceptable location for each subject. Stimulator placement was determined to be acceptable 
when repeatable and measurable quadriceps contractions were obtained. Stimulator placement 
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was marked on the subject’s skin with an indelible marker to insure repeatability of the 
location and measurement. A typical twitch force curve for the MagStim 200 stimulator is 
pictured below. Typical stimulator output required to achieve supramaximal stimulation has 
been found to be a mean of 83% of stimulator output.  
 
Figure 8: Twitch tension versus MagStim power output (Polkey et al., 1996). Twitch tension plateaus at a mean 
power output of 83% using a MagStim 200 stimulator (MagStim Co. Ltd., Whitland, Dyfed, Wales). 
 
Assessment of fatigue 
Prior to and immediately following the cycle ergometer time trial, an assessment of 
quadriceps twitch force (Qtw,pot) was performed. Twitch force prior to the time trial was used 
as a baseline for twitch force obtained after the time trial. The assessment of fatigue protocol 
consisted of six repetitions of potentiation and magnetic stimulation with 30 seconds of rest 
between repetitions. For each repetition, subjects performed a maximal voluntary isometric 
contraction (MVC) of the quadriceps muscle for 5 seconds. At the end of the 5 second MVC, 
the subject received a supra-maximal magnetic stimulation of the femoral nerve, and a second 
stimulation after 5 seconds of rest. The force produced during the second twitch of each 
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repetition was recorded as Qtw,pot. Force values from the first two repetitions were discarded 
based on previous findings that the degree of potentiation is smaller after the first two 
measurements (Amann et al., 2007). Force values from the final four repetitions were 
averaged to produce a Qtw,pot force value for each trial. 
Delayed Onset Muscle Soreness 
Quadriceps soreness was assessed using a numeric rating pain scale with “no 
soreness” indicated at one end (score 0) and “unbearably painful” at the other (score 10) 
(Downie et al., 1978). The subject stood with hands on hips and feet approximately shoulder 
width apart. The subject was asked to squat down to 90° (internal angle), rise to the start 
position and then indicate on the numeric scale the soreness felt in the lower limbs (Twist & 
Eston, 2005). 
Skeletal Muscle Troponin I 
Blood samples (10 mL) were taken from the antecubital vein prior to supplementation, 
following 26 days of supplementation, immediately following the downhill running protocol 
and at 2, 24, 48, 72, and 96 hours following the downhill running protocol. Each sample was 
put on ice for 30 minutes and centrifuged at 3000 RPM for 20 minutes. Plasma was pipetted 
into 4-6 storage tubes. Red-blood cells were stored in Vacutainer® into which the sample was 
collected. Plasma samples were stored at -80ºC until being analyzed. RBC samples were also 
stored at -80ºC but were not analyzed during this study. 
Skeletal muscle troponin I, (Uscn Life Science Inc., Wuhan, Hubei PRC) was 
analyzed from plasma using enzyme-linked immunoassay (ELISA) according to the 
manufacturer’s instructions. An ELx405TM Automated Plate Washer (Bio-Tek® Instruments, 
Inc., Winooski, VT) was used to wash the 96-well microplates during the pre-assay 
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preparations. The assay was performed using a Powerwave XSTM Spectrophotometer (Bio-
Tek® Instruments, Inc., Winooski, VT). 
Data Analysis 
Data were analyzed using SPSS 20.0 (IBM Corporation, Chicago, IL, USA) statistical 
software. Dependent variables were analyzed for each condition for differences with a one-
way, within-factors repeated measures analysis of variance (ANOVA) within groups and a 
priori independent t-test between groups to analyze simple main effects. Mauchly’s test was 
conducted to determine whether sphericity was violated. If sphericity was violated, the 
repeated-measures ANOVA was corrected using the Greenhouse–Geiser correction factor. 
Statistical significance was set at p < 0.05. Data are presented as mean ± standard deviation. 
To determine an appropriate sample size for the study, post-hoc power analysis of 
existing literature was conducted using G*Power version 3.0.5 (Universität Kiel, Germany) 
(Faul, Erdfelder, Lang, & Buchner, 2007). Effect sizes are presented as mean differences 
between groups divided by standard deviation. Based on previous literature (Fontani et al., 
2005; Guezennec et al., 1989; Santos et al., 2012; Tartibian et al., 2009, 2011), achieving an 
experiment-wise error rate of 0.05 required 15 subjects within each treatment group. In two 
studies, Tartibian et al. (2009, 2011) has shown that ingestion of ω3FAs (n=9-15) for 30 days 
compared to placebo/control (n=9-15) significantly reduced inflammatory markers and 
perceived pain and symptoms following eccentric exercise, with effect sizes ranging from 
0.64-0.75 for a study power of 0.82 and 0.84 respectively. Santos et al. (2012) showed that 
following 30 days ω3FA supplementation (n=10), compared to placebo (n=10), a number of 
inflammatory markers were decreased directly after 5 days of military survival boot camp 
(increased physical stress/restricted caloric intake) for effect sizes ranging from 0.61-0.75 for 
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study power of 0.84. A sample size of 20 per group was chosen to provide an expected 96% 
power to detect differences. Study power was expected to be maintained at 80% if five 
subjects withdrew or were dropped from each group in the study. 
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CHAPTER 4  
RESULTS 
The purpose of this study was to evaluate whether PCSO-524™ supplementation 
attenuates EIMD-related endurance exercise performance impairment, peripheral muscle 
fatigue and symptoms of DOMS in untrained men following eccentric exercise.  
Thirty-two subjects (treatment group: n=16, placebo: n=16) completed the study. 
Subject characteristics (Table 4) did not differ significantly (p > .05) for age, height, BMI or 
VO2max and relative VO2max. Mass was significantly different between groups (p < .05). 
Table 4: Subject Characteristics 
 PCSO-524™ Placebo p 
Age 21.7 ± 1.7 21.5 ± 2.4 0.80 
Height (cm) 178.1 ± 5.8 174.2 ± 6.7 0.09 
Mass (kg) 74.8 ± 8.8 66.6 ± 9.7 0.02 
BMI 23.6 ± 2.9 21.9 ± 2.8 0.10 
V̇O2max (L) 3.38 ± 0.50 3.00 ± 0.63 0.07 
VO2max relative 
(mL/kg/min) 
46.4 ± 6.2 45.63 ± 6.1 0.73 
20 Minute Cycle Ergometer Time Trial Performance 
Because body mass between the groups was significantly different, power output was 
compared both for mean power and mean power relative to body mass. There were no 
significant differences (p > .05) in power output between groups due to the supplement or 
within groups due to eccentric exercise on cycle ergometer time trial performance.  
Mean power output during the time trial did not change significantly after eccentric 
exercise for the treatment (F = .106, p = .75) or placebo groups (F = .122, p = .73) (Table 5). 
Mean power output relative to body mass did not change significantly after eccentric exercise 
for treatment (F = .077, p = .79) or placebo subjects (F = .288, p = .60) (Table 6). 
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No significant differences were found in mean power output between groups before 
supplementation (T = 1.079, p = .29) or after eccentric exercise (T = .1.410, p = .17). No 
significant differences were found in mean power output relative to body mass between 
groups before supplementation (T = .258, p = .80) or after eccentric exercise (T = .026, p = 
.98).  
Table 5: Time Trial Power Output, Pre-Supplementation and 24 hours Post-Eccentric Exercise 
(Mean ± SD) 
Power Output (watts) PCSO-524™ Placebo 
Pre-Supplementation 153.3 ± 36.5 139.1 ± 38.2 
24H Post-Downhill Run 154.9 ± 30.9 137.8 ± 37.3 
 
Table 6: Time Trial Relative Power Output, Pre-Supplementation and 24 hours Post-Eccentric 
Exercise (Mean ± SD) 
Relative Power Output 
(watts/kg) 
PCSO-524™ Placebo 
Pre-Supplementation 2.07 ± .46 2.11 ± .57 
24H Post-Downhill Run 2.08 ± .39 2.08 ± .55 
 
RPE increased significantly for each group during each time trial (p < .05 for each 
group and time trial). The treatment group had significantly higher RPE at the end of the 
second time trial compared to the first (T = 2.3, p = .04; 95% CI = .05 – 1.32). The placebo 
group had significantly higher RPE at the beginning of the second time trial compared to the 
first (T = 2.356, p = .03; 95% CI = 0.13 – 2.61). RPE was not different between groups at 0, 5, 
10, 15 or 20 minutes during the pre-supplementation time trial (p > .05 for all time points) and 
the post-supplementation time trial (p > .05 for all time points) (Table 4 and Table 5). 
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Table 7: Rate of Perceived Exertion during Pre-Supplementation Time Trial 
Time (min) PCSO-524™ Placebo p 
0 8.6 ± 1.5 8.7 ± 1.9 .92 
5 12.6 ± 1.6 12.8 ± 2.0 .70 
10 14.5 ± 1.6 14.6 ± 1.8 .92 
15 15.9 ± 1.5 15.9 ± 1.8 1.00 
20 17.3 ± 1.8 17.3 ± 1.9 .92 
 
Table 8: Rate of Perceived Exertion during Post-Eccentric Exercise Time Trial 
Time (min) PCSO-524™ Placebo p 
0 9.0 ± 1.9 10.1 ± 2.6 .19 
5 12.8 ± 1.3 12.9 ± 2.2 .84 
10 14.6 ± 1.2 14.6 ± 2.0 .92 
15 15.8 ± 1.4 15.5 ± 2.0 .69 
20 17.9 ± 1.8 17.3 ± 1.8 .36 
 
The treatment group had significantly lower heart rate during the post-
supplementation time trial at 5 minutes (T = 2.311, p = .04; 95% CI = 0.6 – 15.4) and 10 
minutes (T = 2.239, p = .04; 95% CI = 0.3 – 13.4) compared to the pre-supplementation time 
trial. The placebo group did not have any significant differences during any point of the two 
time trials (p > .05 for 0, 5, 10, 15, 20 minute time points). Heart rate was significantly lower 
in the treatment group only at the start of the second time trial (Table 9) compared to the 
placebo group (treatment: 106 ± 17 bpm, placebo: 127 ± 18 bpm, p < .01). No other 
significant differences (p > .05) were found for heart rate between groups during the two time 
trials.  
Table 9: Heart Rate during Pre-Supplementation Time Trial 
Time (min) PCSO-524™ Placebo p 
0 113 ± 19 122 ± 15 .16 
5 153 ± 16 160 ± 18 .25 
10 159 ± 15 167 ± 17 .22 
15 162 ± 14 172 ± 14 .08 
20 171 ± 12 180 ± 14 .07 
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Table 10: Heart Rate during Post-Supplementation Time Trial 
Time (min) PCSO-524™ Placebo p 
0 106 ± 17 127 ± 18 < .01 
5 145 ± 18 157 ± 21 .09 
10 153 ± 19 165 ± 19 .08 
15 158 ± 16 169 ± 21 .09 
20 172 ± 14 181 ± 16 .13 
Delayed Onset Muscle Soreness 
Muscle soreness increased in both groups after the eccentric exercise protocol, 
peaking between 24 and 48 hours and declining toward baseline at 72 and 96 hours (Error! 
Reference source not found.). Significant effects for time were found in the treatment group 
(F = 22.071, p < .001) and placebo group (F = 15.108, p < .001). Pairwise comparisons 
between groups at each time point revealed significantly lower DOMS in the treatment group 
at 72 hours (T = 2.475, p < .05; 95% CI = 0.252 – 2.623) and 96 hours (T = 2.100, p < .05; 
95% CI = 0.038 – 2.712). No significant differences (p > .05 for all time points) were found 
between groups at pre-supplementation, post-supplementation, 24 hours post-DHR and 48 
hours post-DHR (Table 11). 
Table 11: DOMS Pain Scores 
Time point PCSO-524™ Placebo p 
Pre-supplementation 2.1 ± 1.5 2.1 ± 1.5 .66 
Post-
supplementation 
1.8 ± 1.8 1.4 ± 1.5 .53 
24H Post-Run 4.5 ± 2.5 4.4 ± 2.1 .88 
48H Post-Run 4.3 ± 2.0 4.8 ± 1.8 .46 
72H Post-Run 2.5 ± 1.5 3.9 ± 1.8 .02 
96H Post-Run 1.6 ± 1.4 2.9 ± 2.2 .04 
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Figure 9: Quadriceps muscle soreness was lower at 72 and 96 hours post-eccentric exercise in the treatment 
(PCSO-524™ marine lipid fraction, n=16) group compared to placebo (n=16). Soreness is a numeric rating scale 
from 0 (no pain) to 10 (unbearably painful). Bars represent SE. * denotes significant difference between groups 
(p < .05) 
Potentiated Quadriceps Twitch 
Data is presented as a percent change in quadriceps twitch force (Qtw,pot) from pre-time 
trial to post-time trial. Post-hoc paired, one-tailed t-tests revealed that treatment group Qtw,pot 
did not change significantly (T = .38, p > .05) between time trials, but the placebo group 
Qtw,pot change did significantly (T = 2.095, p < .05) between time trials. Between group 
differences in Qtw,pot were non-significant for the pre-supplementation time trial (p = .21) and 
the 24hrs post-eccentric exercise time trial (p = .34) (Table 12). It should be noted that post-
supplementation quadriceps twitch data was not collected from one subject due to equipment 
error. Additionally, one outlier score was removed from the placebo group, leaving 16 PCSO-
524™ subjects and 14 placebo subjects for this measure. The outlier score in the placebo 
group demonstrated a 211% increase in Qtw,pot from pre- to post-time trial at 24 hours post-
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eccentric exercise, which is 3.4 SD from the mean with this score included and 7.1 SD from 
the mean with the score excluded. 
Table 12: Percent Change in Qtw,pot following cycling time trial 
Qtw,pot % Change  
(Pre to Post Time Trial) 
PCSO-524™ Placebo p 
Pre-Supplementation 
Time Trial 
-27.8 ± 26.2 -23.9 ± 24.0 .669 
24hrs Post-Eccentric 
Exercise Time Trial 
-30.4 ± 14.3 -39.5 ± 24.3 .243 
 
 Figure 10: Potentiated quadriceps twitch force (Qtw,pot) decreased significantly (p < .05) in the placebo group 
(n=16) after the post-eccentric exercise cycle ergometer time trial while no changes were observed in the 
treatment group (n=16). Bars are SE. * denotes significant difference between trials (p < .05) 
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Figure 11: Concentration of slow skeletal troponin I in blood was higher at 2 – 96 hours in the placebo group 
(n=16) following eccentric exercise compared to the treatment group (n=16). Bars are SE. * denotes significant (p 
< .05) difference between groups. 
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) were found for skeletal muscle troponin I for the treatment group (F = 30.964, p < 
.001) and the placebo group (F = 74.733, p < .001). Pairwise comparisons (Error! Reference 
source not found.) between groups at each time point revealed significant differences at 2 
hours (T = 2.562, p < .05; 95% CI = 0.9 – 8.0), 24 hours (T = 3.561, p < .01; 95% CI = 4.4 – 
15.4), 48 hours (T = 4.095, p < .001; 95% CI = 4.7 – 14.0), 72 hours (T = 3.222, p < .01; 95% 
CI = 2.5 – 11.2) and 96 hours post-downhill run (T = 2.177, p < .05; 95% CI = 0.3 – 10.4). 
Differences between groups were not significant (p > .05) at pre-supplementation, post-
supplementation and 0 hours post-eccentric exercise. 
Table 13: Slow Skeletal Troponin I Appearance in Blood 
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sTnI (ng/ml) PCSO-524™ Placebo T p 
Pre-supplementation 7.7 ± 3.3 8.4 ± 3.1 .613 .54 
Post-supplementation, pre-run 7.1 ± 3.8 7.8 ± 3.5 .504 .62 
0 hours post-run 10.7 ± 4.2 13.2 ± 4.5 1.651 .11 
2 hours post-run 13.5 ± 4.2 17.9 ± 5.6 2.562 .02 
24 hours post-run 20.3 ± 6.0 30.2 ± 9.0 3.651 < .01 
48 hours post-run 18.6 ± 5.8 28.0 ± 7.1 4.095 < .001 
72 hours post-run 16.7 ± 5.0 23.6 ± 6.8 3.222 < .01 
96 hours post-run 11.4 ± 5.7 16.7 ± 8.1 2.177 .04 
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Figure 11: Concentration of slow skeletal troponin I in blood was higher at 2 – 96 hours in the placebo group 
(n=16) following eccentric exercise compared to the treatment group (n=16). Bars are SE. * denotes significant 
(p < .05) difference between groups. 
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Decision on the Hypotheses 
1. Twenty minute cycling time trial mean power output was not greater in the PCSO-
524™ supplementation group compared to the placebo group after eccentric exercise.  
Hypothesis 1 was rejected. 
2. Potentiated quadriceps twitch force decreased less following a 20 minute cycling time 
trial in the PCSO-524™ supplementation group compared to the placebo group. 
Hypothesis 2 was accepted. 
3. The concentration of skeletal troponin I (sTnI) in blood was lower in the PCSO-524™ 
supplementation group compared to the placebo group following eccentric exercise. 
Hypothesis 3 was accepted. 
4. Perceived quadriceps soreness during squatting was less in the PCSO-524™ 
supplementation group compared to the placebo group following eccentric exercise. 
Hypothesis 4 was accepted.  
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CHAPTER 5 
DISCUSSION 
The purpose of this study was to evaluate whether or not endurance exercise 
performance, quadriceps muscle fatigue, muscle damage and muscle soreness following 
eccentric exercise by untrained men can be affected by PCSO-524™ marine lipid fraction 
supplementation. The data demonstrate that quadriceps muscle soreness, muscle fatigue and 
muscle damage can be lessened through chronic PCSO-524™ supplementation. However, 
endurance exercise performance following eccentric exercise was not affected by PCSO-
524™ supplementation. 
Delayed Onset Muscle Soreness 
A novel finding of this study was that untrained men chronically supplemented with 
PCSO-524™ experienced less muscle soreness from 72 to 96 hours following eccentric 
exercise. DOMS-related pain was lower at 72 hours (treatment: 2.5 ± 1.5, placebo: 3.9 ± 1.8, 
p < .05) and 96 hours (treatment: 1.6 ± 1.4, placebo: 2.9 ± 2.2, p < .05) in the PCSO-524™ 
group compared to placebo. PCSO-524™ contains EPA, DHA and furan fatty acids, all 
molecules that have been found to inhibit the chain of events leading to DOMS (Wakimoto et 
al., 2011; Whitehouse et al., 1997).  
Previously, PCSO-524™ supplementation had been found to attenuate DOMS in 
runners (Baum et al., 2013). Similar to Baum et al. (2013), the present study found PCSO-
524™ was effective in attenuating symptoms of DOMS following strenuous exercise. Baum 
et al. (2013) noted a slight but significant reduction in DOMS in the 48 hours following a 
30km run in runners who supplemented with 8 capsules PCSO-524™ per day for 11 weeks 
compared to no changes in DOMS for runners supplementing with a placebo. Median DOMS 
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scores in the PCSO-524™ group fell from 3.5 to 2.0 from the pre-supplementation to post-
supplementation 30km run (p < .05), but no changes were found in the placebo group (median 
DOMS: pre = 2.0, post = 2.0, p > .05). In the present study, muscle soreness was lower in the 
treatment group at 72 and 96 hours following eccentric exercise but not at 24 – 48 hours as in 
Baum et al. (2013). The reason for the different time course for muscle soreness is unclear, 
although the cycling time trial at 24 hours post-eccentric exercise may have delayed recovery 
from muscle soreness in our study. 
PCSO-524™ supplementation was most effective in alleviating symptoms of DOMS 
among runners who trained less than three times per week in the Baum et al. (2013) study, 
which is consistent with data from the present study. The present study confirms the finding 
that less well trained subjects respond to PCSO-524™ supplementation, as the subjects were 
all untrained men. 
The inflammatory processes that are activated in response to exercise-induced muscle 
damage, and which PCSO-524™ supplementation can affect, involves a cascade of events 
which can lead to DOMS. Following a muscle cell damaging event, an influx of calcium into 
disrupted sarcomeres can activate PLA2, which attacks membrane phospholipids and release 
fatty acids such as arachidonic acid (AA) (Gissel, 2005). When arachidonic acid is 
metabolized through the COX and 5-LOX pathways, pro-inflammatory prostaglandins and 
leukotrienes are produced. The production of these proteins and their diffusion into the 
intercellular space attracts monocytes to the area of injury. Monocytes then convert to 
macrophages that phagocytize the affected area and can produce reactive oxygen (ROS) 
species (Yaqoob & Calder, 1995). Edema, caused by an influx of fluid into the muscle, 
increases pressure in the muscle, which is thought to activate sensory neurons and lead to pain 
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felt as DOMS (Appell et al. 1992, Hasson et al. 1993). While an important step in the healing 
process, unchecked or overactive immune response to muscle damage may lead to additional 
damage and delayed recovery from muscle damage (Miller, Bailey, Barnes, Derr, & Hall, 
2004). 
The components PCSO-524™ have been shown to affect two aspects of the cascade of 
events leading to DOMS. First, EPA and DHA inhibit AA metabolism by replacing AA in the 
cell membrane (Heller, Koch, Schmeck, & van Ackern, 1998; Thies et al., 2001). When 
muscle damage occurs, activated PLA2 may disrupt membrane phospholipids, but the 
metabolism of EPA and DHA leads to less inflammatory 3-series prostaglandins and 5-series 
leukotrienes. Secondarily, furan fatty acids may be able to provide an antioxidant effect on 
ROS produced by macrophages in damaged muscle cell, limiting any further damage that 
could be caused by ROS (Wakimoto et al., 2011). Antioxidant supplementation such as 
Vitamin C has previously been shown to attenuate DOMS (Bryer & Goldfarb, 2006), and the 
furan fatty acids in PCSO-524™ may have a similar effect. In a mouse model, evidence of 
secondary muscle damage due to ROS was observed at three days post-exercise (A McArdle 
et al., 1999). In the present study, DOMS scores began to differ between treatment and 
placebo groups at three days post-eccentric exercise (treatment: 2.5 ± 1.5, placebo: 3.9 ± 1.8, 
p < .05). While speculative, the time course observed in the present study may suggest that a 
decrease of oxidative stress by furan fatty acids played a role in the observed results, which 
may be an avenue for future research. 
In contrast to Baum et al. (2013) and the present study, Pumpa et al. (2011) did not 
find significant differences in DOMS after a downhill running protocol among subjects 
supplementing with PCSO-524™. Training status of the subjects in the Pumpa et al. (2011) 
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study may have contributed to the results observed with PCSO-524™ supplementation in 
relation to symptoms of EIMD. In the Pumpa et al. (2011) study, subjects were exclusively 
well-trained men participating in a variety of sports including Australian Football, cycling, 
middle and long-distance running and rugby. Given that less well trained individuals 
responded more to PCSO-524™ supplementation in the Baum et al. (2013) study and the 
present study, while well-trained individuals did not respond to supplementation in the Pumpa 
et al. (2011) study, it is possible that training status has some effect on the efficacy of PCSO-
524™ supplementation in relation to DOMS. 
Additionally, PCSO-524™ supplementation dosage may have contributed to the 
differences among these studies. Subjects in the Pumpa et al. study (2011) consumed four 
PCSO-524™ capsules per day (200 mg active lipid extract) for eight weeks. The present 
study used twice the dosage at eight capsules per day (400 mg lipid extract) for thirty days. 
Baum et al. (2013) reported supplementation of eight capsules per day (400 mg lipid extract) 
for 11 weeks. In studies investigating the effects of NSAIDs on DOMS symptoms, the 
supplement dosage has been found to be a factor in the effectiveness of treatment. Studies of 
ibuprofen as a treatment for DOMS have found contradictory results at difference dosages 
(Gulick et al., 1996). 
The results for DOMS pain scores in the present study are consistent with the findings 
of Tartibian et al. (2009), where PUFA supplementation resulted in reduced indices of EIMD 
including muscle soreness, thigh circumference and range of motion. Tartibian et al. (2009) 
used fish oil (324 mg/day EPA, 216 mg/day DHA) supplemented over 30 days. Indices of 
DOMS were significantly lower at 48 hours in the treatment group (n=9) compared to the 
control (n=9) and placebo (n=9) groups.  
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Time Trials 
The primary focus of the present study was to investigate the effects of eccentric 
exercise and PCSO-524™ supplementation on endurance exercise performance. While 
PCSO-524™ has not been investigated specifically as an ergogenic aid during exercise, ω3FA 
have been investigated for ergogenic effects during exercise. PCSO-524™ contains a high 
proportion of ω3FA (21% EPA, 13% DHA, 6% other ω3FA by weight) (Wolyniak et al., 2005) 
and the results from ω3FA supplementation research may apply to PCSO-524™ 
supplementation. The present study did not find a significant change in 20 min time trial 
performance (pre-supplementation: 153.3 ± 36.5 W, post-supplementation: 154.9 ± 30.9 W, p 
> .05) in subjects supplemented with PCSO-524™ for thirty days.  
Previous research has found that vertical jumping impairs endurance cycling 
performance in a 5 minute cycle ergometer time trial (Twist & Eston, 2009). In contrast, our 
data showed that 20 minute cycling performance is not affected by a previous bout of 
eccentric exercise. Several differences in the design of the present study and that of Twist and 
Eston (2009) may account for these differences, including the eccentric exercise protocol, 
endurance performance test and subject characteristics. 
The present study used untrained men as subjects, while Twist and Eston (2009) used 
physically active male subjects. The exercise performance testing protocol used in the present 
study consisted of a 20 minute time trial. In contrast, Twist and Eston used a 5 minute time 
trial. Additionally, Twist and Eston (2009) used a vertical jumping protocol to induce muscle 
damage while the present study used a downhill running protocol. Vertical jumping exercise 
would be expected to recruit primarily Type II muscle fibers, while in the present study, 
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exercise intensity was chosen at 70% of HRR to primarily target Type I fibers for fatigue and 
muscle damage. 
 Twist and Eston (2009) found significant decreases in mean power output during a 5 
minute time trial following a vertical jumping protocol (baseline: 262.8 ± 17.7 W, 48 hours 
post-exercise: 232.8 ± 15.3 W; p < .05). In contrast, the present study did not find a change in 
20 minute power output at 24 hours post-eccentric exercise with a mean power output during 
the pre-supplementation time trial of 146.2 ± 37.5 W among all subjects and during the post-
downhill run time trial of 146.3 ± 34.8 W (p > .05). 
Other studies have reported decrements in endurance exercise tasks following 
eccentric exercise, which contrast with the results of the present study. Doncaster and Twist 
(2012) observed that bench press exercises resulted in decreased strength and increased 
soreness in the elbow flexors and extensors at 24 and 48 hours following exercise. In the 
performance measure for this study, time-to-exhaustion during cycling arm cranking at 80% 
of the difference between ventilatory threshold and VO2peak was lower in eccentric exercise 
subjects compared to control (treatment: 207.2 ± 91.9 sec, control: 293.4 ± 75.6 sec, p = 
0.036). Burt and Twist (2011) found decreased performance among recreationally active 
subjects (n = 8, 7 men, 1 woman) in a 15 minute cycling time trial (preloaded with 5 minutes 
at ventilatory threshold) at 48 hours following plyometric exercises designed to cause EIMD 
(pre-exercise: 189.71 ± 38.19 W, post-exercise: 168.79 ± 37.68 W, p < .05). Marcora and 
Bosio (2007) also reported decreased endurance running performance during a 30 minute time 
trial at 48 hours following EIMD. 
However, not all researchers have found decrements in endurance exercise 
performance following EIMD. Gleeson et al. (1998) did not observe a significant change in 
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time to exhaustion during cycling after bench stepping exercise. This result is similar to the 
lack of change in cycling performance seen in the present study after downhill running. Peak 
blood lactate was higher in the DOMS condition during the cycle ergometer exercise test, 
while V̇O2peak, HRpeak and endurance time were not significantly different. A possible 
explanation is additional recruitment of type II glycolytic muscles, which may explain 
increased blood lactate without a change in endurance performance (Gleeson et al., 1998). 
However, blood lactate was not measured in the present study, so it is not possible to conclude 
that increased recruitment of type II muscle fibers occurred. 
Potential explanations for the lack of effect on cycling performance from eccentric 
exercise in the present study may be related to the timing of the exercise test relative to 
EIMD, the characteristics of the subjects and their relative unfamiliarity with high-intensity 
cycling. Previous studies (Burt & Twist, 2011; Marcora & Bosio, 2007; Twist & Eston, 2005, 
2009) tested endurance performance at 48 hours following EIMD, while the present study 
tested endurance performance at 24 hours following EIMD. DOMS has been reported to peak 
24 – 48 hours following EIMD (Tiidus, 2008). Cycling sprint performance was previously 
tested at 24 and 48 hours following EIMD and was reduced at both time points (Twist & 
Eston, 2005). It is possible, although unknown, that exercise performance in the present study 
may have been different if tested at 48 hours following EIMD. 
Additionally, the training status of subjects in the present study and lack of familiarity 
with cycling and high-intensity exercise in general may have contributed to the lack of 
difference in performance following eccentric exercise. All subjects completed a 
familiarization time trial in the present study, which has been shown to improve reliability in 
subsequent time trials (Noreen, Yamamoto, & Clair, 2010). However, subjects in the Noreen 
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et al. (2010) study were trained cyclists who were familiar with time trials and high intensity 
cycling. Additionally, their study utilized an onscreen pacer during the second and third time 
trials, while the present study did not. In a different study, Zavorsky et al. (2007) found that 
time trial performance repeatability was higher in more highly trained cyclists (mean power: 
285 ± 33 W)  compared to recreationally trained cyclists (mean power: 204 ± 34 W) during a 
simulated 20 km time trial. In the present study, time trial performance following downhill 
running decreased in seventeen subjects (range: -26 to -1 W) and increased in fifteen subjects 
(range: 1 to 44 W). In light of the range of performance changes observed, the repeatability of 
the test among the subjects tested may have been an issue. 
Peripheral Muscle Fatigue 
Quadriceps muscle fatigue has previously been measured following an exercise task 
through magnetic stimulation of the femoral nerve and measurement of potentiated quadriceps 
twitch force (Kufel et al., 2002; Polkey et al., 1996). This measure provides a non-volitional 
“quantitative estimate of the degree of contractile fatigue elicited by the exercise” (Mador, 
Bozkanat, & Kufel, 2003). Quadriceps twitch force is measured before and after the exercise 
task and the percentage of force decrement from baseline is taken as the level of fatigue. 
Quadriceps muscle fatigue following a cycling time trial, measured through 
potentiated quadriceps twitch force, was significantly different between groups in the present 
study. The placebo group experienced a significant decline in quadriceps twitch force after the 
post-eccentric exercise time trial compared to a baseline time trial (pre-supplementation: -23.9 
± 24.0%, post-eccentric exercise: -39.5 ± 24.3%, p < .05). The PCSO-524™ group, however, 
did not show a change in quadriceps fatigue from the pre-supplementation time trial to the 
post-eccentric exercise time trial (pre-supplementation: -27.8 ± 26.2%, post-DHR: -30.4 ± 
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14.3%, p > .05). This suggests that PCSO-524™ supplementation has a protective effect on 
muscle damage during eccentric exercise and allows subjects to engage in intensive cycling 
exercise while inducing less quadriceps muscle fatigue. 
The level of potentiated quadriceps twitch force fatigue observed in the present study 
is similar to levels of fatigue observed previously (Kufel et al., 2002). Kufel et al. investigated 
both potentiated (Qtw,pot) and unpotentiated (Qtw,unpot) following 10, 15, 20 and 30 MVC 
maneuvers of 5 seconds each. Qtw,pot fell by as much as about 40% after 30 MVC maneuvers, 
which compares to the 39.5 ± 24.3% fall in Qtw,pot observed in the present study in the placebo 
group after the downhill run and final cycling time trial exercise. 
There is some evidence for a contractile fatigue protective effect from PUFA 
supplementation. PUFA supplementation can be effective in providing fatigue resistance in rat 
peripheral muscles during long-duration exercise (Peoples & McLennan, 2010, 2013). Rats 
were fed diets with fat content modified to either saturated fat, n-3 PUFA or n-6 PUFA. The n-
3 PUFA diet contained a high proportion of DHA (28.9%) and EPA (9%), which are two 
primary components of PCSO-524™. Rats fed fish oil were more highly resistant to fatigue 
during continuous muscle twitch contractions and showed reduced skeletal muscle O2 
consumption during exercise and recovery (Peoples & McLennan, 2013). 
Slow Skeletal Troponin I 
The present study is the first to measure slow sTnI in plasma in response to an anti-
inflammatory nutritional supplementation and eccentric exercise. The data indicate that 
eccentric exercise induced significant changes in slow sTnI plasma levels and PCSO-524™ 
supplementation attenuated the appearance of slow sTnI compared to placebo (p < .05). 
Significant differences in sTnI levels were observed at 2 hours following eccentric exercise 
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and persisted at 24, 48, 72 and 96 hours (p < .05). Peak sTnI levels observed in the present 
study (treatment: 20.3 ± 6.0 ng/ml, placebo: 30.2 ± 9.0 ng/ml) are comparable to those 
reported in bone injury (16 ± 2 ng/ml) and soft-tissue injury (10 ± 2 ng/ml) patients (Onuoha 
et al., 2001). The data from the present study indicate that the eccentric exercise bout caused 
muscle damage and disruption of structural protein troponin I. 
Skeletal troponin I has been proposed as an alternative serum marker of skeletal 
muscle damage to commonly used markers such as creatine kinase (CK) and myoglobin (Mb) 
concentrations (Sorichter et al., 1997). These three markers have limitations as markers of 
muscle damage and a more specific protein marker is desirable. Proteins normally found in 
the cytoplasm of muscle cells such as CK and Mb are commonly used as markers of muscle 
damage following intensive exercise. However, CK has been observed to be highly variable 
following comparable exercise-induced muscle damage, which limits its usefulness when 
being used to examine differences in muscle damage between interventions (Clarkson & 
Ebbeling, 1988; K Nosaka & Clarkson, 1996). Mb is similarly found primarily in muscle cell 
cytoplasm and its appearance in blood following muscle damage indicates damage to the 
muscle cell membrane (Dahlqvist, Voss, Lauridsen, Krag, & Vissing, 2014). 
Skeletal muscle troponin I (sTnI) is a structural protein in the sarcolemma involved in 
the regulation of muscle cell contraction (Plowman & Smith, 2011). Due to its location in the 
cell and specificity to muscle cells, sTnI has been investigated as a marker of damage specific 
to the contractile structure, providing information about permeability of the muscle cell 
membrane and disruption of structural elements (Dahlqvist et al., 2014).  
sTnI has previously been found to increase in plasma following exercise-induced 
muscle damage as a result of downhill running (Sorichter et al., 1997). Sorichter et al. (1997) 
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found sTnI levels peaked about 6 hours following downhill running at 27.3 µg/ml (27300 
ng/ml). In the present study, baseline slow sTnI levels were 8.4 ± 3.1 ng/ml in the placebo 
group and increased to 30.2 ± 9.0 ng/ml at 24 hours following the downhill running bout. 
There are differences among reported slow sTnI levels in the literature. sTnI increased in 
response to eccentric knee extensor exercise from 71.34 ± 26.58 ng/ml to 128.55 ± 40.49 
ng/ml (Willoughby, 2003), which is a higher rate of appearance than the current study but 
lower than that seen by Sorichter et al (1997). It is not clear why there is a large variation in 
the levels of sTnI observed in these studies. Sorichter et al. (1997) did not report whether fast 
or slow sTnI was measured. It is possible that the assay used was not specific to either 
isoform. 
It is possible that the different manufacturers of assays used in these studies 
contributed to some of the differences observed. Another explanation may be the mode of 
exercise and the training status of the subjects in each study. Sorichter et al. (1997) used 
physical education teacher trainees, but did not describe the training status. It is likely that the 
subjects were somewhat active since they were involved in physical education. Willoughby et 
al. (2003) used recreationally active but non-trained men. The present study used untrained 
subjects who were specifically screened to minimize any recent exercise experience. 
In addition to the levels of sTnI observed in the present study compared to previous 
studies, the general time course of sTnI appearance and return to baseline is of interest. In the 
present study, sTnI had increased from baseline by two hours, peaked at 24 hours and returned 
to baseline about 96 hours following downhill running. The time course observed by Sorichter 
et al. (1997) was somewhat different, with a peak at 6 hours post-run and the decline toward 
baseline having already begun at 24 hours and returning to baseline by 48 hours. One 
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difference to note is that the present study included the cycling time trial bout at 24 hours 
following downhill running, which may have introduced additional muscle damage. 
Willoughby et al. (2003) measured sTnI through 48 hours where levels for eccentric exercise 
were still elevated (98.30 ± 34.32 ng/ml). Additionally, the time course of fast sTnI 
appearance and return to baseline following elbow flexor exercises was observed to peak at 
96 hours (Chapman et al., 2013). Since the exercise used by Chapman et al. (2013) was 
maximal contractions, Type II muscle fibers were damaged (as demonstrated by increased fast 
sTnI levels) but Type I muscle fibers were not (slow sTnI levels did not increase). The time 
course observed by Willoughby et al. (2003) is more similar to the present study than those 
observed by Sorichter et al. (1997). Clearly, there is variability in the time course of sTnI that 
likely depends on the mode of exercise, the degree of muscle damage introduced and the 
subject population. 
Future Directions 
The present study has demonstrated that PCSO-524™ supplementation attenuates 
symptoms of DOMS and peripheral muscle fatigue following eccentric exercise in untrained 
men. Muscle damage was induced by the downhill running protocol and less muscle damage 
was observed with PCSO-524™ supplementation compared to placebo, as evidenced by slow 
sTnI levels in the hours and days following exercise.  Further research is needed to determine 
whether a dose-dependent treatment effect can be observed and whether different modes of 
exercise are affected differently by PCSO-524™ supplementation.  
The present study did not find a difference in cycling endurance performance 
following an eccentric exercise bout. Future performance-based research is needed to 
determine whether PCSO-524™ attenuates performance decrements that follow eccentric 
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exercise, using a protocol that reliably results in performance changes following eccentric 
exercise. If untrained subjects are studied, then a previously validated eccentric exercise 
protocol such as vertical jumping and a different cycling performance trial such as that used 
by Twist and Eston (2009) may be considered. 
Evidence exists that use of NSAIDs may retard adaptation to training stimulus and 
prolong recovery in exercise-damaged muscles (Machida & Takemasa, 2010; Warden, 2009). 
Thus, the benefits of the pain relieving effects of these drugs may be outweighed by the long-
term potential negative effects from their use. It has not been determined if PUFA 
supplementation during exercise has the same drawbacks. In contrast, PUFA supplementation 
has been found to improve protein synthesis in healthy adults, older adults and patients 
recovering from esophageal cancer surgery (Noreen, Sass, et al., 2010; Ryan et al., 2009; 
Smith et al., 2011). Future research is needed to determine if the anti-inflammatory effects of 
PCSO-524™ are accompanied by the detrimental effects of reduced adaptation to training 
stimulus as seen with other anti-inflammatory treatments. 
Further research in this area may wish to look more closely at the relationship between 
PCSO-524™ and DOMS. Data from the present study and Baum et al. (2013) suggest that 
PCSO-524™ may be an effective pain reliever following intensive exercise that causes 
muscles soreness. PCSO-524™ has been shown to be an effective anti-inflammatory and has 
effects on the cyclooxygenase and 5-lipoxygenase pathways, which is similar to popular 
pharmaceutical treatments such as NSAIDs.  
Conclusions 
In summary, this study is the first to demonstrate that muscle soreness in untrained 
men following eccentric exercise can be decreased with a prior period of PCSO-524™ 
 
  
77 
 
supplementation. The reduction in DOMS symptoms was seen in the 72 to 96 hours following 
exercise. Based on data from the present study and previously demonstrated effectiveness of 
PCSO-524™ as a treatment for inflammation-related conditions such as arthritis, it is possible 
that reduced inflammation is one mechanism by which DOMS can be decreased. Endurance 
exercise performance in untrained males is not affected by a bout of eccentric exercise taking 
place 24 hours prior. Cycling time trial performance among untrained men following eccentric 
exercise is not affected by thirty days of PCSO-524™ supplementation. Quadriceps muscle 
twitch force decreased less among PCSO-524™ subjects following a cycling time trial, 
indicating that PCSO-524™ supplementation can lessen muscle fatigue during endurance 
exercise that follows a prior bout of eccentric exercise. This has implications for PCSO-524™ 
in endurance athletic activities where strength endurance impairment may be a competitive 
disadvantage. These data further demonstrate the complexity of exercise-induced muscle 
damage, delayed onset muscle soreness and endurance exercise performance. PCSO-524™ 
supplementation appears to be a viable treatment for the purpose of attenuating DOMS, 
peripheral muscle fatigue following endurance exercise, and muscle damage resulting from 
eccentric exercise, but has no effect on exercise performance in untrained men. 
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INDIANA UNIVERSITY INFORMED CONSENT STATEMENT FOR 
 
 Effect of Marine Lipid Fraction PCSO-524™ on Markers of Exercise-Induced Muscle 
Damage and Cycling Endurance Performance in Untrained Males 
 
You are invited to participate in muscle damage research.  We are studying the effect of a lipid 
extract on exercise performance.  The extract is from New Zealand green-lipped mussel (Omega 
XL®).  You were selected as a possible subject because: 1) you’re male, 2) you’re 18-30 years old, 
and 3) you exercise not more than three times per week and not more than 30 minutes each time that 
you exercise.   
Please read this form.  You should get any questions answered before starting the study. 
The study is being conducted by Dr. Timothy D. Mickleborough, David Platt and Jacob Sinex, 
Department of Kinesiology, Indiana University.  It is funded by Pharmalink International Ltd. 
 
STUDY PURPOSE 
The purpose of this study is to determine if taking lipid extract for thirty days reduces muscle 
damage from intense exercise. 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
If you want to be in the study, you’ll be one of 40 people participating. 
PROCEDURES FOR THE STUDY: 
If you want to be in the study, you’ll visit the lab nine times over about seven weeks. During 
the visits, you will run and ride a bike.  Below is the study schedule.  Items listed as “lab days” mean 
that you must come to the lab to be tested.  “At home” means that you do the task at home on your 
own.  Details about each procedure are included below the Schedule of Study Procedures. 
You are responsible for transportation to and from the lab.  The lab is located at the HPER 
Building at 1025 E. 7th Street, Room 80, Bloomington, IN 47405.  The total amount of time estimated 
to finish the study is under 13 hours.  Parking is free in designated parking spots behind the building. 
 
Schedule of Study Procedures 
Week 1 Visit 1 (Day 0): Lab day: Estimated time 2 hours
 Familiarization Session and 20 Minute Bicycle Time Trial 
On the first day, we’ll check your cholesterol, glucose, and heart rate, and 
take height and weight measurements.  After that you’ll be asked to fill out 
a questionnaire and we’ll answer any questions you might have.  If all your 
values are normal we’ll ask you to ride an exercise bike for 20 minutes as 
fast as you can to become familiar with what it's like to do a time trial for 
the real test.   
Questionnaires and Diary (Days 1-7): At home 
 We ask you to fill out two forms every day.  One enables us to monitor your 
well-being and  mood every day.  The other helps us monitor mood and emotional 
demands for athletes.  Once  a week we will ask you to fill out a longer form on 
how you feel.  Typically these forms will  take about 10 minutes to finish for 
the entire week. 
 
Week 2 Visit 2 (Day 7):  Lab day:  Estimated time 45 minutes
 Maximal Aerobic Exercise Capacity Test  
 We’ll ask you to run on a treadmill at increasing incline levels until you 
decide that you  cannot continue to run at the current incline level. This test is called 
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a VO2 max test.  
 
Questionnaires and Diary (Days 7-14): At home 
 Like the previous week, we will ask you to fill out forms monitoring your 
activity, well-being,  and mood every day. 
 
Week 3 Visit 3 (Day 14): Lab day: Estimated time 20-35 minutes.   
 Measures of Muscle Damage and Soreness 
  We will do various tests to measure your muscle strength and soreness.  
These tests are  expected to take 15-30 minutes.   
 Blood Collection 
 We’ll also collect 2 teaspoons (10 mL) of blood.  This should only take 5 
minutes to finish.   
 
Questionnaires and Diary (Days 14-21): At home 
 Like the previous weeks, we’ll ask you to fill out forms monitoring your 
activity, well-being, and mood every day.   
 
Food Frequency Questionnaire (Days 14-21): At home 
 We will ask you to fill this out on any day you choose between Days 14-21.  
It is just one  form.  You only fill this out once during this period.  It should take 
around 10 minutes to  complete. 
 
Week 4 Visit 4 (Day 21):  Lab Day:  Estimated time 1 hour, 30 minutes 
  
 Measurements of Peripheral Muscle Fatigue   
 We will measure your muscle fatigue before and after the 20 minute time 
trial. 
 
 Pulmonary Function Test 
 We’ll test your lung function before and after the 20 minute time trial.   
 
 20 Minute Cycling Time Trial 
 You will ride an exercise bike for 20 minutes as fast as you can. 
 
Supplementation 
You begin taking the supplement or placebo (a pill that looks like the 
supplement but does not have the active ingredients) after this lab visit.  
You will take eight capsules per day (4 in the morning and 4 in the evening) 
until the end of the study. 
 
Questionnaires and Diary (Days 21-28): At home 
 Like the previous weeks, we’ll ask you to fill out forms monitoring your 
activity, well-being, and mood every day.   
 
Weeks 
5-7 
Supplementation (Days 28-47): At home
 
 You will not visit the lab during this period.  You will continue taking eight 
capsules each day (4 in the morning and 4 in the evening) during weeks five 
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through seven.      
 
Questionnaires and Diary (Days 28-47): At home 
 Like the previous weeks, we’ll ask you to fill out forms monitoring your 
activity, well-being, and mood every day.  
 
 
 
 
Weeks 
7-8 
Visit 5 (Day 47): Lab Day:  Estimated time 3 hours, 20 minutes 
Measures of Muscle Damage and Soreness 
We will do various tests to measure your muscle strength and soreness at 
the beginning of this visit.  These tests are expected to take 15-30 minutes.   
Blood Collection 
We’ll also collect 2 teaspoons (10 ml) of blood at the beginning of this visit.  
This should take about 5 minutes. 
Downhill-Running Regimen 
We'll have you run downhill on a modified treadmill for 20 minutes.  
Including setup, this test should take no longer than 35 minutes. 
Blood Collection 
We will ask you to wait in the lab for 2 hours watching TV, reading or 
otherwise sitting quietly after you complete the downhill running.  After 2 
hours, we’ll collect 2 teaspoons (10 ml) of blood.  This should take about 5 
minutes. 
 
Food Frequency Questionnaire (Days 47-50): At home 
We will ask you to fill this out on any day you choose between days 47-50.  
It is just one form.  You only fill this out once during this period.  It should 
take about 10 minutes to complete. 
 
Visit 6 (Day 48): Lab day: Estimated time 1 hour, 30 minutes 
We’ll ask you to come back to the lab 24 hours after your last visit at the 
same time of day for the following tests and measures.    
Measures of Muscle Damage and Soreness 
We will do various tests to measure your muscle strength and soreness at 
the beginning of this visit.  These tests are expected to take 15-30 minutes.   
Blood Collection 
We’ll also collect 2 teaspoons (10 ml) of blood at the beginning of this visit.  
This should take about 5 minutes. 
Measurements of Peripheral Muscle Fatigue   
We will measure your muscle fatigue before and after the 20 minute time 
trial. 
 
20 Minute Cycling Time Trial 
You will ride an exercise bike for 20 minutes as fast as you can. 
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Visit 7 (Day 49): Lab day: Estimated time 1 hour 
We’ll ask you to come back to the lab 24 hours after your last visit at the 
same time for the following tests and measures.   
Measures of Muscle Damage and Soreness 
We will do various tests to measure your muscle strength and soreness at 
the beginning of this visit.  These tests are expected to take 15-30 minutes.   
Blood Collection 
We’ll also collect 2 teaspoons (10 ml) of blood at the beginning of this visit.  
This should take about 5 minutes. 
Pulmonary Function Test 
We’ll test your lung function.   
 
Visit 8 (Day 50): Lab day: Estimated time 30 minutes 
We’ll ask you to come back to the lab 24 hours after your last visit at the 
same time for the following tests and measures. 
Measures of Muscle Damage and Soreness 
We will do various tests to measure your muscle strength and soreness at 
the beginning of this visit.  These tests are expected to take 15-30 minutes.   
Blood Collection 
We’ll also collect 2 teaspoons (10 ml) of blood at the beginning of this visit.  
This should take about 5 minutes. 
 
Visit 9 (Day 51): Lab day: Estimated time 30 minutes 
We’ll ask you to come back to the lab 24 hours after your last visit at the 
same time for the following tests and measures. 
Measures of Muscle Damage and Soreness 
We will do various tests to measure your muscle strength and soreness at 
the beginning of this visit.  These tests are expected to take 15-30 minutes.   
Blood Collection 
We’ll also collect 2 teaspoons (10 ml) of blood at the beginning of this visit.  
This should take about 5 minutes. 
 
Questionnaires and Diary (Days 47-51): At home 
Like the previous weeks, we’ll ask you to fill out forms monitoring your 
activity, well-being, and mood every day. 
 
Prescreening 
To ensure that you’re healthy enough for this study, we’ll check your cholesterol.  This 
involves a finger prick to collect a few drops of blood.  We’ll run your blood through a machine 
specially built for this purpose.  We’ll check your blood sugar in a similar manner.  We will check your 
height with a ruler, weight by standing still on a scale.  We’ll also measure blood pressure with a cuff, 
and heart rate using an infrared device that we’ll place on your finger.  We’ll also ask you to fill out a 
16 question Yes/No survey.  Based on this information, this will tell us if you can safely participate in 
the study. 
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Activity Diary 
We’ll ask you to keep an exercise log.  We’ll ask you to write down how many times you 
exercise and for how long.  We'll also want you to write down how you exercise and how hard it was. 
  
Daily Analysis of Life Demands of Athletes (DALDA) Questionnaire 
This survey monitors your well-being.  We want to make sure that you’re healthy throughout 
the study.  You’ll fill out a survey about your general outlook on life.  This form has two parts. One 
part asks you about the sources of stress.  The other part asks you about how moody or stressed out 
you feel. We also want to know any health changes that occur during the study.  You should fill this 
form out the same time every day.  The DALDA is 34 questions long. 
 
Profile of Mood States (POMS) Questionnaire 
We’ll ask you to complete another mood questionnaire each day in the morning. There is a 
short version of the form that we’ll ask you to fill out six out of seven days each week. The number of 
questions for the short form is 37 questions.  There is a long version of the form with 65 questions that 
we’ll ask you to fill out once per week.  The questions ask you how you feel right now.  Question 
types include how happy you feel or how much energy you have, for example. 
 
Food Frequency Questionnaire 
We’ll ask you to complete a questionnaire about what you eat before starting the supplement 
and again at the end of the 30-day supplementation period.  This form helps us see if changes in your 
diet will affect the results.  This questionnaire has 27 questions.  If you have questions about changing 
your diet during the study, ask us.  We’re here to help! 
 
Supplementation 
After the second time trial, we’ll ask you to begin taking some capsules.  The capsules could 
contain the active supplement or olive oil.  The olive oil capsule (placebo) has been shown to not have 
the health benefits of the supplement.  We’ll assign you to either take the olive oil capsule or the actual 
supplement completely by chance. You have an equal chance of being assigned the olive oil capsule or 
the supplement.  Neither you nor the study investigator will know which capsule you are taking during 
the study.  We’ll ask you to take eight capsules a day, on the schedule of four capsules in the morning 
and four in the evening.  You must return any unused capsules and the containers (even if empty) back 
to us at the next lab day visit. We’ll ask you to record the times that you take the capsules each day on 
the Activity Diary. 
 
20-minute Bicycle Time-Trial  
We’ll set up the exercise bike for you and show you how to use it. After that you can warm up 
at whatever speed you want. Next, we’ll ask you to ride the bike as fast as you can for 20 minutes. You 
can change gears whenever you want.  We’ll ask you to do the 20-minute time trial on your first, 
fourth, and sixth visit to the lab.  While doing the time trials, we’ll measure how much oxygen your 
body is providing the muscles, how much of that oxygen your muscles are using, and how hard your 
heart is working.  The monitors we use to measure these things are non-invasive. We’ll wrap an 
infrared sensor on your leg with an elastic bandage to estimate the amount of oxygen reaching the 
tissues in your leg.  Measuring heart rate requires you to wear a strap around your chest. We will ask 
you to wear a mouthpiece connected to hoses during the time trial so we can collect exhaled gas to 
measure your oxygen consumption and breathing rate. We will ask you to wear a nose clip so all of 
your breathing will be through your mouth. 
 
Rating of Perceived Exertion and Shortness of Breath: We’ll ask how hard it was to 
exercise during your bicycle time trial tests in the lab.  We use two scales: a 15 point rating of 
perceived exertion (how hard you feel like you are working) and a 10 point scale to rate your difficulty 
of breathing.   We’ll do this every 4 minutes while you’re riding the bike. 
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Maximal Aerobic Capacity Exercise Test   
This test measures your highest exercise capacity.  Top athletes take this test to see how fit they are.  
We’ll give you an opportunity to become familiar with the equipment and warm up before the test.   
We’ll make sure that you’re ready before beginning the test.  You will wear a mouthpiece connected to 
hoses during the test and your nose will be plugged with a nose clip.  We’ll also take your heart rate 
with a monitor.  For the start of the test, you will sit for 5 minutes while we get resting measurements.  
Then you will get up and begin running on the treadmill at an easy pace. We’ll ask you to continue 
running while we increase the grade (incline) 2% every three minutes until you decide that you can’t 
run anymore.  At that point you’ll have completed the test.  If at any point you feel dizzy or 
lightheaded, let us know.  Safety is our number one priority.  After the test, you will cool down by 
running or walking at an easy pace.  
 
Pulmonary function:  
We will measure how well your lungs are functioning with two devices.  One measures lung airflow.  
Another device measures lung air pressure. Both tests require you to inhale and exhale as fast as you 
can while sitting down. Each device requires you to blow through a tube.  Your nose will be plugged 
with nose clips.  We’ll have you do three trials to measure airflow.  If the results aren’t within 10% of 
each other we’ll ask you to do more trials until we get three that have results that are close enough to 
each other.  The test for air pressure measures how strong your breathing muscles are.  This test will be 
done 5 times separated by 30 seconds.  If the results are not close enough to each other, we will ask 
you to do more tests. 
 
Downhill-Running Regimen:  
We’ll ask you to run for 20 minutes downhill (-16 º grade) on a treadmill. This test will be performed 
on your fifth visit to the lab.  You will warm up by running slowly while the treadmill is flat.  We’ll 
then decrease the grade to -16º and ask you to run at a moderate pace (a percentage of the pace that 
you ran during the maximal aerobic exercise capacity test).  After 20 minutes, you will cool down by 
running or walking at an easy pace.  We’ll ask you to wear a mouthpiece to measure how much 
oxygen your muscles are using and a heart rate monitor. You’ll probably feel sore for about one week 
after you are finished running.  You’ll feel this most likely in your legs.  
 
Measurements of Peripheral Muscle Fatigue  
Before and after the 20 minute bicycle time trials, we’ll ask you to do some leg extensions in your 
right leg. We’ll ask you to be seated with your leg bent. Your leg will be wrapped above your ankle.  
We will stimulate the muscles in your thighs with a wire and a small voltage which you should feel 
like a small pull in your leg.  Three single pulls will be obtained with breaks of 30 seconds between 
each one.  We'll increase the voltage intensity from 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100% 
of safe allowed voltage by the machine.  We’ll ask you to contract your quads as hard as you can for 5 
seconds. At the end of the 5 seconds, we will stimulate your nerve twice with 5 seconds of rest in 
between.  After 30 seconds of rest, we will repeat this procedure 5 times.  We’ll do these tests on your 
third, fifth, sixth, seventh, eighth, and ninth visits to the lab.    
 
Blood Collection: 
We will be drawing blood from a vein in your arm. We will collect about 2 teaspoons (10 mL) 8 times 
during the study.  Drawing blood should only take 5 minutes.  In total, we will take about 16 teaspoons 
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of blood from you.   We want to see how much damage your muscles have and how quickly they 
recover from the damage.  
 
One of the tests that we will be using measures how your body modifies muscle cells in response to 
muscle damage.  We will not be profiling your DNA for any specific markers or genes. 
 
Measures of Muscle Damage and Soreness 
We will check for muscle pain a few ways.  We’ll ask you to lie on your stomach on a table with your 
legs outstretched and measure how much you can flex your leg.  We will also check for swelling by 
measuring around your thigh.  We’ll also measure how much power your muscles can produce.  We 
have a special leg extension machine that measures force.  We’ll ask you to sit in a chair and push a 
bar away from you with your leg.  We’ll give you a chance to familiarize yourself with it before 
actually doing measurements.  Additionally, we’ll ask you about how much pain you’re having in your 
legs.  We’ll measure it by asking you to squat and tell us how painful it is.   Finally, we’ll measure pain 
with a device that measures a certain amount of pressure.  After pushing on your thighs, we’ll ask you 
how much it hurts.  
 
RISKS OF TAKING PART IN THE STUDY: 
While on the study, the risks and discomforts are:  
1. Supplementation: Common side effects of the supplement include vomiting, nausea, bloating, 
and burping.  Rare side effects include easy bleeding/bruising and serious allergic reactions.  
In people allergic to shellfish, the supplements can cause a serious allergic reaction.   Signs of 
serious allergic reactions include feelings of a "lump" in the throat, hoarseness, or feeling 
tightness in the chest and/or audible wheezing, nausea, vomiting, stomach pain, diarrhea.  You 
might also have an allergic reaction if your skin turns red or becomes swollen with raised, 
itchy bumps.   
2. Maximal exercise testing on a treadmill: Risks for this test include lightheadedness, chest 
discomfort, leg cramps, significant leg fatigue, nausea, occasional irregular heartbeats, and 
abnormal blood pressure responses. The risk of heart attack during this test, although minor 
(approximately 1 to 2 in 10,000), does exist.  There is also a small risk of contamination or 
infection from the mouthpieces.   
3. Downhill treadmill running:  The risk of death while performing this type of exercise is about 
the same as drowning in a bathtub.  The likelihood that you will have leg pain for along time 
after you finish the study is also minimal.  You may also have shortness of breath, muscle 
soreness or cramping, and lightheadedness.  A few days after the test, we expect you to have 
moderate to severe muscle soreness in your legs.  Pain should disappear by about one week 
after the test. 
4. Time Trial on Exercise Bicycle: You may feel discomfort due to being unfamiliar with being 
seated on a bicycle while exercising for a sustained period of time. You may also have wrist 
pain, shoulder pain, neck pain, back pain, buttocks pain, leg pain and numbness in your hands 
and/or feet. 
5. Peripheral Muscle Fatigue Testing: You may have temporary dizziness, fainting, or nausea 
during this test.  Additionally, the electrodes might cause your skin to be irritated.  You could 
develop a rash if you have sensitive skin.  During stimulation you may be surprised by the 
involuntary muscle contraction or experience discomfort in your legs. 
6. Blood Draw: You may have fainting, soreness, bruising, infection from drawing blood, and/or 
swelling at the site where we draw your blood.   
7. Pulmonary Function Testing: You may experience headache, light-headedness, or possibly 
fainting.   
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8. Measures of Muscle Damage and Soreness: You could have some pain and discomfort from 
the pressure sensitivity testing. You may also have pain or be injured while lifting weights 
with your legs.  Additionally, you will be performing this test after completing the downhill 
running test which is intended to produce muscle damage. We expect that you will experience 
some pain or discomfort while completing this test. 
9. Questionnaires/Diary: You might have anxiety or discomfort when filling out these forms. 
10. There is also a risk of loss of confidentiality: such as computers could be hacked or have a 
virus and data taken which would identify you with your collected data.  Examples of data 
could be name, addresses, and the results of tests. 
 
To minimize the risks listed above, the following measures will be employed:  
1. During any of the tests or trials, you can ask to stop the test or trial and we will stop right 
away. 
2. Supplementation: If you are allergic to shellfish or fish oil then you will not be able to 
participate in the study. You should report any adverse effects or unusual symptoms to the 
principal investigator. 
3. Maximal exercise testing on a treadmill: We will use a disposable mouthpiece whenever 
possible.  When rubber mouthpieces are used, they will be cleaned in a detergent solution and 
disinfected following each use.  High risk subjects, such as subjects that are overweight, have 
allergies to fish products, or have a history of muscle soreness, asthma or cardiac problems, 
will be unable to participate in the study.  Trained researchers will monitor you during the test.   
4. Downhill treadmill running: We’ll monitor your heart rate and breathing and stop the test if 
you have any adverse effects. 
5. Time Trial on Cycle Ergometer: We’ll ensure that you’re comfortable on the bike before 
starting.  We’ll make any modifications or adjustments to the bike to ensure your comfort.  
We’ll monitor your heart rate and stop the test if you have any adverse effects. 
6. Peripheral Muscle Fatigue Testing: You will be sitting during this test to minimize injury if 
you faint.  If it is too painful you can request us to stop the test. 
7. Blood Draws: You will be sitting to minimize injury if you faint.  Sites will be sterilized, and 
trained individuals will draw blood to minimize the risk of infection.   
8. Pulmonary Function Testing: You will be sitting during these tests to minimize injury if you 
faint.  If severe wheezing begins, the test will be immediately stopped and you will be given 
oxygen if necessary. 
9. Measures of Muscle Damage and Soreness: You will be able to tell us if you are experiencing 
too much pain and the tests will be stopped at that time. 
10. Questionnaires/Diary: If you are uncomfortable with any questions, you can choose not to 
answer them.  Also, we’ll monitor your responses during the supplementation period and 
compare them to responses before you began the supplement.  If there are large changes, we’ll 
refer you to IU Health for consultation. 
11. Confidentiality: We’ll keep all data in a locked room on password-protected computers with 
virus protection in rooms with limited access. 
 
BENEFITS: 
You are not expected to benefit from participating in this study.  However, you will have access to all 
of your own data regarding your personal lung function and markers of inflammation. 
 
ALTERNATIVES TO TAKING PART IN THE STUDY: 
 
You can choose not to participate in this study. 
 
CONFIDENTIALITY 
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Efforts will be made to keep your personal information confidential.  Data will be stored on password-
protected computers in locked rooms with limited public access.  We cannot guarantee absolute 
confidentiality.  Your personal information may be disclosed if required by law.  Your identity will be 
held in confidence in reports in which the study may be published and databases in which results may 
be stored. 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the study investigator and his/her research associates, the IU 
Institutional Review Board or its designees, and (as allowed by law) state or federal agencies, 
specifically the Office for Human Research Protections (OHRP) who may need to access the collected 
research data. 
 
PAYMENT 
You will be paid $1,000 for taking part in this study. We’ll pay you as follows: 
 
First lab visit  $0   
Second lab visit:  $30  
Third lab visit:   $30  
Fourth lab visit  $30  
Fifth lab visit  $230  
Sixth lab visit  $200  
Seventh lab visit $160   
Eighth lab visit   $160   
Ninth lab visit  $160  
 
You will be compensated for completing each session.  If you withdraw from the study, you 
will be compensated for the completed visits.  If you discontinue a test in the middle of a lab visit, you 
will be paid on a rate of $10 per hour for that visit in addition to payment for the completed visits. 
Payments will be made after each session and mailed to an address that you specify.  If you would 
prefer, we can wait and mail the entire amount after you are done participating in the study.  Payment 
takes about 3 weeks for the university to process and send out the check. 
 
COMPENSATION FOR INJURY 
In the event of physical injury resulting from your participation in this research, necessary 
medical treatment will be provided to you and billed as part of your medical expenses.  Costs not 
covered by your health care insurer will be your responsibility.  Also, it is your responsibility to 
determine the extent of your health care coverage.  There is no program in place for other monetary 
compensation for such injuries.  However, you are not giving up any legal rights or benefits to which 
you are otherwise entitled.  Because you are participating in research which is not conducted at a 
medical facility, you will be responsible for seeking medical care and for the expenses associated with 
any care received. 
 
CONTACTS FOR QUESTIONS OR PROBLEMS: 
If you have any questions about the study or the procedures, or you experience adverse effects 
as a result of participating in this study, you may contact Jacob Sinex or David Platt (812-856-9126) or 
Dr. Timothy D. Mickleborough (812-855-0753).  If you cannot reach the researchers during regular 
business hours (i.e., 8:00AM-5:00PM), please call the IU Human Subjects Office at (812) 856-4242 or 
(800) 696-2949.  
For questions about your rights as a research participant or to discuss problems, complaints or 
concerns about a research study, or to get information, or give input, contact the IU Human Subjects 
office at (812) 856-4242 or (800) 696-2949. 
 
VOLUNTARY NATURE OF STUDY 
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Taking part in this study is voluntary.  You may choose not to take part or may leave the study 
at any time.  Leaving the study will not result in any penalty or loss of benefits to which you are 
entitled.  Your decision whether or not to participate in this study will not affect your current or future 
relations with the investigators or Indiana University.  The Principal Investigator may remove subjects 
from the study if it felt that subjects are not abiding by the restrictions placed on subjects entering the 
study. 
 
SUBJECT’S CONSENT 
In consideration of all of the above, I give my consent to participate in this research study.   
I will be given a copy of this informed consent document to keep for my records.  I agree to 
take part in this study. 
 
 
Subject’s Printed Name:  
 
Subject’s Signature: Date:
             (must 
be dated by the subject) 
 
Printed Name of Person Obtaining Consent:  
 
Signature of Person Obtaining Consent: Date:
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APPENDIX B 
MEDICAL QUESTIONNAIRE 
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Modified Physical Activity Readiness Questionnaire (PAR-Q 
Name Email 
DOB Age Phone 
Yes No Have you been ever been told by a physician that you have cardiac, peripheral vascular, or cerebrovascular disease? 
Yes No Have you ever been told by a physician that you have COPD, asthma, interstitial lung disease, or cystic fibrosis? 
Yes No Have you ever been told by a physician that you have Diabetes mellitus (types 1 and 2), thyroid disorders, renal or liver disease? 
Yes No Have you ever felt or do you currently experience pain, discomfort in the chest, neck, jaw, arms, or other areas? 
Yes No Have you ever felt or do you currently experience shortness of breath at rest or with mild exertion?  
Yes No Have you ever felt or do you currently experience dizziness or a loss of consciousness at rest or during mild exercise? 
Yes No Have you ever felt or do you currently experience shortness of breath when lying flat or severe shortness of breath and coughing that generally occurs at night? 
Yes No Have you ever had or currently have swelling of the feet or ankles?  
Yes No Have you ever experienced or currently experience rapid heart beat under resting conditions or does your heart skip beats under any conditions? 
Yes No 
Have you ever experienced or currently experience intermittent muscle pain (ache, cramp, 
numbness or sense of fatigue) in your calf muscle, which occurs during exercise and is relieved 
by rest. 
Yes No Have you ever been told by a physician that you have that you have a known heart murmur? 
Yes No Have you ever experienced or currently experience unusual fatigue or shortness of breath with usual activities? 
Yes No Are you a current cigarette smoker or quit within the previous 6 months or are routinely exposed to environmental tobacco smoke? 
Yes No Do you have a father, brother or son with heart disease before the age of 55 years old or a mother, sister or daughter with heart disease before the age of 65 years old? 
Yes No Do you currently participate in more than 30 min of moderate intensity physical activity on at least three days of the week for at least three months? 
Yes No Are you currently taking any medication (prescription or over the counter)?  If yes, please list on 
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the reverse side. 
Signature Date 
Regular exercise is associated with many health benefits, yet any change of activity may increase the 
risk of injury. By signing you affirm that you have read each question carefully and answered every 
question honestly.   
 
Medications you’re currently taking 
Name Reason for taking 
  
  
  
  
 
Height________(m)  Calculated BMI ___________ 
Weight ________(kg)      
Blood Pressure  _________/__________ mm Hg 
Cholesterol (HDL only)  ____________________ mg/dL   
Blood glucose ____________________ mg/dL   
Resting Heart Rate ____________________ bpm 
 
For Office use only:  
Risk Stratification:   
   Low       Moderate       High 
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APPENDIX C 
PERSONAL HISTORY QUESTIONNAIRE 
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Subject#:  Study #: 1211009997 
 
General Personal History Questionnaire 
 
 
How many days per week do you typically exercise? 
1 2 3 4 5 6 7 
 
How long is your typical exercise session? 
Less than  
30 minutes 
30 – 60 
minutes 
60 – 120  
minutes 
over 120 
minutes 
 
Indicate your status for each of the following: 
I have been diagnosed with asthma or exercise-induced 
asthma.  Yes  No 
I have participated in a strength training program during 
the past 60 days.  Yes  No 
I consume fish oil or other omega-3 nutrition 
supplements on a regular basis.  Yes  No 
I frequently run up and downhill or up and down stairs 
for exercise.  Yes  No 
I have a history of experiencing pain in my hips or 
knees.  Yes  No 
I have an allergy to fish, seafood, or shellfish.   Yes  No 
 
 Do you take any medications, supplements or vitamins?  Yes        No 
If yes, write name, amount, frequency, and how long you have taken them: 
Name of 
medication or 
supplement 
How much How 
often 
How long taking it  
(in weeks, months, years) 
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APPENDIX D 
SUPPLEMENTATION AND EXERCISE DIARY 
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Subject#:  Study #: 1211009997 
 
Exercise and Supplementation Log 
Date Supplement  
Time Taken #1 
Supplement  
Time Taken #2 
Type of Exercise Minutes 
Exercised 
Perceived 
Exertion 
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APPENDIX E 
DATA COLLECTION SHEETS 
  
 
  
117 
 
Subject #: Visit 1 Data Collection Sheet Study #: 12110009997 
 
Date: 
Time 
from 
Start 
HR RPE Dyspnea Average Power 
Average 
RPM 
Rest  --- --- --- --- 
0 min    ---- ---- 
5 min      
10 min      
15 min      
20 min      
 
Seat Height (cm): 
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Aerobic Capacity Data Collection Sheet 
Subject:     Weight: (kg)   Date:   
Pbar   
Rel 
Hum:   
Mode: Run Temp:   
VO2max Filename:   Target RPM:   
Target Pace (mph):   
Time (min) Speed (mph) Grade (%) RPM HR 
0 Rest - -   
1 Rest - -   
2 Rest - -   
3 Rest - -   
4 Rest - -   
5 run - 1 mph 0     
6 run - 1 mph 0     
7 run 0     
8   0     
9   0     
10 run 4     
11   4     
12   4     
13 run 6     
14   6     
15   6     
16 run 8     
17   8     
18   8     
19 run 10     
20   10     
21   10     
  FEO2 FECO2 VE stpd VE btps VO2 VCO2 VO2ml RER fb 
Max                   
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Subject: Visit 3 Data Sheet Date: 
Algometer Site 15 cm distal to the ASIS 
4 cm proximal 
to the SPP 
midpoint of 
the ASIS and 
SPP along the 
axis 
2 cm lateral of 
midpoint 
Trial 1         
Trial 2         
Trial 3         
Average         
  Squatting Soreness Score 
Thigh 
Circumference 
(cm) 
Knee Flexion 
ROM 
(degrees) 
Knee Flexion 
Iso Torque (v) 
Trial 1         
Trial 2         
Trial 3         
Average       
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Subject: Visit 4 Data Sheet Date: 
Pulmonary Function 
(Pre) FVC FEV1 
FEF25-
75   Height (cm): 
Trial 1         
Trial 2         Weight (kg): 
Trial 3         
Time Trial 
Seat 
Height 
(cm): 
Average 
Power 
(watts) 
Average 
RPM HR RPE Dyspnea 
Rest --- --- ---   --- --- 
0 Min --- ---       
5 Min ---           
10 Min ---           
15 Min ---           
20 Min ---           
Pulmonary Function 
(Post) FVC FEV1 
FEF25-
75   
Trial 1         
Trial 2         
Trial 3         
Supplement Bag # 
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Subject: Visit 5 Data Sheet Date: 
Algometer Site 15 cm distal to the ASIS 
4 cm 
proximal to 
the SPP 
midpoint of 
the ASIS and 
SPP along 
the axis 
2 cm lateral 
of midpoint 
2 cm medial 
of midpoint 
Trial 1           
Trial 2           
Trial 3           
Average           
  
Squatting 
Soreness 
Score 
Thigh 
Circumferen
ce (cm) 
Knee 
Flexion 
ROM 
(degrees) 
Knee 
Flexion Iso 
Torque (v) 
  
Trial 1           
Trial 2           
Trial 3           
Average       
 
Minute HR RPE Pace 
Rev 
Count 
0         
5         
10         
15         
20         
Blood Collection   Max HR:   
Time 1:   Rest HR:   
Time 2:   HRR:   
Time 3:   
70% 
HRR:   
Target 
HR:   
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Subject: Visit 6,7,8,9 Data Sheet Date: 
   
Algometer Site 15 cm distal to the ASIS 
4 cm 
proximal to 
the SPP 
midpoint of 
the ASIS and 
SPP along 
the axis 
2 cm lateral 
of midpoint 
2 cm medial 
of midpoint 
Trial 1           
Trial 2           
Trial 3           
Average           
  
Squatting 
Soreness 
Score 
Thigh 
Circumferen
ce (cm) 
Knee 
Flexion 
ROM 
(degrees) 
Knee 
Flexion Iso 
Torque (v) 
  
Trial 1           
Trial 2           
Trial 3           
Average       
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APPENDIX F 
RAW DATA – CYCLING TIME TRIAL PERFORMANCE 
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Subject Group 
Pre-Sup 
Mean_Power 
Post-Run 
Mean_Power 
80 Placebo 138 122 
67 Placebo 141 143 
56 Placebo 119 116 
52 Placebo 203 202 
46 Placebo 118 119 
25 Placebo 104 101 
60 Placebo 132 122 
54 Placebo 148 122 
31 Placebo 178 185 
4 Placebo 170 189 
23 Placebo 117 120 
20 Placebo 155 146 
3 Placebo 94 89 
103 Placebo 219 202 
105 Placebo 90 93 
108 Placebo 99 134 
  Mean: 139.1 137.8 
  SD: 38.2 37.3 
  CV: 0.275 0.271 
45 Treatment 182 180 
53 Treatment 145 148 
96 Treatment 164 145 
8 Treatment 140 170 
85 Treatment 140 154 
98 Treatment 134 141 
10 Treatment 185 182 
70 Treatment 256 230 
6 Treatment 124 113 
113 Treatment 143 119 
110 Treatment 151 136 
117 Treatment 133 134 
40 Treatment 87 131 
116 Treatment 143 141 
104 Treatment 180 201 
118 Treatment 146 153 
  Mean: 153.3 154.9 
  SD: 36.5 30.9 
  CV: 0.238 0.199 
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Subject Group HR_0_Pre HR_5_Pre  HR_10_Pre HR_15_Pre HR_20_Pre
80 Placebo 125 160  165 169 172 
67 Placebo 115 162  171 174 174 
56 Placebo 130 156  176 182 188 
52 Placebo 114 171  181 187 193 
46 Placebo 118 169  176 176 188 
25 Placebo 104 128  143 164 179 
60 Placebo 102 136  146 160 169 
54 Placebo 145 180  185 181 187 
31 Placebo 103 174  174 179 195 
4 Placebo 138 162  171 174 179 
23 Placebo 130 165  172 176 190 
20 Placebo 138 169  168 164 185 
3 Placebo 130 164  167 174 184 
103 Placebo 141 182  182 182 187 
105 Placebo 108 163  174 179 179 
108 Placebo 108 119  117 125 136 
  Mean: 121.8 160  166.8 171.6 180.3 
  SD: 14.6 17.7  17.5 14.5 14 
  CV: 0.12 0.111  0.105 0.084 0.078 
45 Treatment 62 176  171 176 182 
53 Treatment 114 171  184 182 180 
96 Treatment 120 163  165 172 186 
8 Treatment 121 158  174 169 167 
85 Treatment 105 128  134 138 144 
98 Treatment 126 160  169 174 185 
10 Treatment 143 181  181 178 185 
70 Treatment 129 145  156 160 171 
6 Treatment 114 135  138 136 176 
113 Treatment 129 148  156 160 176 
110 Treatment 82 141  154 162 167 
117 Treatment 116 175  174 176 178 
40 Treatment 122 140  142 153 154 
116 Treatment 111 145  151 150 164 
104 Treatment 107 141  148 150 171 
118 Treatment 110 140  154 162 160 
  Mean: 113.2 152.9  159.4 162.4 171.6 
  SD: 19.1 16.4  15.2 14.1 11.9 
  CV: 0.169 0.107  0.095 0.087 0.069 
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Subject Group 
HR_0 
Post 
HR_5 
Post 
HR_10 
Post 
HR_15 
Post 
HR_20 
Post 
80 Placebo 111 152 158 162 171
67 Placebo 135 156 160 167 174
56 Placebo 110 140 158 171 188
52 Placebo 126 176 185 190 197
46 Placebo 138 178 178 181 194
25 Placebo 96 117 130 132 176
60 Placebo 110 128 133 128 133
54 Placebo 144 160 162 166 180
31 Placebo 139 170 188 190 194
4 Placebo 148 171 177 185 185
23 Placebo 141 164 171 176 190
20 Placebo 140 182 188 182 190
3 Placebo 114 143 141 145 171
103 Placebo 154 182 182 200 197
105 Placebo 97 164 176 179 185
108 Placebo 121 128 152 152 167
  Mean: 126.5 156.9 164.9 169.1 180.8
  SD: 18.3 20.5 18.9 20.9 16.1
  CV: 0.145 0.131 0.115 0.124 0.089
45 Treatment 82 156 162 160 174
53 Treatment 76 160 171 169 188
96 Treatment 99 145 154 156 179
8 Treatment 109 176 182 188 194
85 Treatment 121 140 146 152 154
98 Treatment 129 160 167 171 190
10 Treatment 134 174 176 179 181
70 Treatment 125 150 145 150 171
6 Treatment 102 136 128 142 155
113 Treatment 110 124 120 129 169
110 Treatment 97 132 152 143 156
117 Treatment 104 150 176 177 190
40 Treatment 117 126 133 147 154
116 Treatment 90 118 126 150 171
104 Treatment 113 148 158 162 179
118 Treatment 90 124 145 148 154
  Mean: 106.1 144.9 152.6 157.7 172.4
  SD: 16.8 17.7 19.2 15.8 14.4
  CV: 0.158 0.122 0.126 0.1 0.084
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Subject Group 
RPE_0 
Pre 
RPE_5 
Pre 
RPE_10 
Pre 
RPE_15 
Pre 
RPE_20 
Pre 
80 Placebo 9 13 15 17 18
67 Placebo 7 13 15 15 16
56 Placebo 7 10 12 13 15
52 Placebo 11 14 15 17 19
46 Placebo 7 12 13 15 17
25 Placebo 6 12 14 15 15
60 Placebo 8 12 14 17 18
54 Placebo 10 17 18 17 18
31 Placebo 7 14 16 17 19
4 Placebo 7 10 13 15 17
23 Placebo 7 10 13 15 17
20 Placebo 12 15 17 18 20
3 Placebo 11 13 14 15 17
103 Placebo 11 15 16 17 19
105 Placebo 9 14 16 19 19
108 Placebo 10 11 12 12 13
  Mean: 8.7 12.8 14.6 15.9 17.3
  SD: 1.9 2 1.8 1.8 1.9
  CV: 0.218 0.156 0.123 0.113 0.11
45 Treatment 12 16 17 16 17
53 Treatment 7 13 17 19 19
96 Treatment 9 13 15 18 20
8 Treatment 9 13 14 15 15
85 Treatment 7 13 15 17 17
98 Treatment 7 12 14 16 17
10 Treatment 7 9 12 15 18
70 Treatment 10 14 15 16 17
6 Treatment 6 13 14 15 19
113 Treatment 9 13 15 15 18
110 Treatment 8 12 14 16 17
117 Treatment 9 13 17 18 20
40 Treatment 9 11 12 13 13
116 Treatment 9 10 12 14 15
104 Treatment 10 13 15 16 17
118 Treatment 10 13 14 15 17
  Mean: 8.6 12.6 14.5 15.9 17.3
  SD: 1.5 1.6 1.6 1.5 1.8
  CV: 0.174 0.127 0.11 0.094 0.104
 
Subject Group RPE_0 RPE_5 RPE_10 RPE_15 RPE_20 
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Post Post Post Post Post 
80 Placebo 7 12 14 14 16
67 Placebo 11 14 15 16 17.5
56 Placebo 10 12 13 14 15
52 Placebo 12 15 18 19 20
46 Placebo 10 13 14 15 19
25 Placebo 6 9 13 13 15
60 Placebo 15 15 16 17 17
54 Placebo 11 14 15 15 17
31 Placebo 10 12 15 17 19
4 Placebo 9 12 13 15 17
23 Placebo 6 9 11 14 17
20 Placebo 12 17 19 19 20
3 Placebo 12 13 14 13 15
103 Placebo 13 15 16 17 19
105 Placebo 7 13 15 17 19
108 Placebo 10 11 13 13 15
  Mean: 10.1 12.9 14.6 15.5 17.3
  SD: 2.6 2.2 2 2 1.8
  CV: 0.257 0.171 0.137 0.129 0.104
45 Treatment 9 15 17 16 17
53 Treatment 9 15 17 18 20
96 Treatment 7 12 14 14 20
8 Treatment 12 13 14 15 17
85 Treatment 10 12 15 16 18
98 Treatment 7 11 13 15 19
10 Treatment 7 11 15 18 20
70 Treatment 7 13 14 15 17
6 Treatment 6 14 15 15 17
113 Treatment 11 14 15 17 20
110 Treatment 10 13 14 16 16
117 Treatment 8 12 15 17 20
40 Treatment 12 12 13 13 15
116 Treatment 9 11 13 14 15
104 Treatment 9 13 14 16 18
118 Treatment 11 13 15 17 18
  Mean: 9 12.8 14.6 15.8 17.9
  SD: 1.9 1.3 1.2 1.4 1.8
  CV: 0.211 0.102 0.082 0.089 0.101
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APPENDIX G 
RAW DATA – DELAYED ONSET MUSCLE SORENESS 
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Group 
Pre 
Sup 
Post 
Sup 
24 hr Post-
Run 
48 hr Post-
Run 
72 hr Post-
Run 
96 hr Post-
Run 
Placebo 2 0 2 4 3 1
Placebo 5 3 3 2 3 3
Placebo 2 3 7 8 7 6
Placebo 2 2 4 3 3 2
Placebo 0 0 1 3 1 1
Placebo 1 0 4 5 4 2
Placebo 5 4 7 6 5 4
Placebo 1 1 8 7 5 2
Placebo 2 1 4 4 3 3
Placebo 2 0 3 3 2 1
Placebo 0 0 2 5 3 1
Placebo 2 3 6 7 7 5
Placebo 1 2 6 4 4 1
Placebo 4 4 3 4 3 2
Placebo 0 0 6 7 7 7
Placebo 1 0 4 5 3 7
Mean: 1.9 1.4 4.4 4.8 3.9 3
SD: 1.6 1.5 2.1 1.8 1.8 2.2
CV: 0.842 1.071 0.477 0.375 0.462 0.733
Treatment 5 3 8 7 4 3
Treatment 3 4 6 4 3 2
Treatment 1 1 1 1 1 1
Treatment 2 1 6 3 2 2
Treatment 3 2 4 5 3 2
Treatment 1 0 1 5 2 3
Treatment 2 1 1 1 0 0
Treatment 0 0 5 6 2 0
Treatment 2 0 4 4 1 1
Treatment 1 0 4 4 2 0
Treatment 0 2 7 5 3 1
Treatment 2 3 5 6 4 1
Treatment 1 0 2 2 1 0
Treatment 4 3 6 5 3 2
Treatment 5 6 9 8 6 5
Treatment 5 6 9 8 6 5
Mean: 2.3 2 4.9 4.6 2.7 1.8
SD: 1.7 2 2.7 2.2 1.7 1.6
CV: 0.739 1 0.551 0.478 0.63 0.889
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APPENDIX H 
RAW DATA – POTENTIATED QUADRICEPS TWITCH 
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Group Pre Sup Post Sup 
Placebo -30.62 -16.85
Placebo -17.73 -40.22
Placebo -12.62
Placebo 0.91 -61.69
Placebo -29.11 -8.33
Placebo -31.41 -31.55
Placebo -56.19 -75.05
Placebo -23.11 -54.17
Placebo -37.34 -34.01
Placebo -9.05 -10.61
Placebo -40.66 -32.91
Placebo 0.95
Placebo 34.3 0.23
Placebo -31.65 -55.56
Placebo -67.12 -65.54
Placebo -32.25 -66.49
Mean: -23.9 -39.5
SD: 24 24.3
CV: -1.004 -0.615
Treatment 2.28 -18.87
Treatment -54.18 -30.01
Treatment -26.14 -42.41
Treatment -23.7 -9.73
Treatment -51.79 -34.05
Treatment -37.17 -47.32
Treatment -41.6 -33.61
Treatment -38.81 -15.29
Treatment -1.78 -50.73
Treatment -52.29 -41.42
Treatment -7.09 0.77
Treatment -16.8 -17.86
Treatment -54.17 -37.29
Treatment 15.22 -40.42
Treatment -68.8 -35.82
Treatment 12.75 -32.2
Mean: -27.8 -30.4
SD: 26.2 14.3
CV: -0.944 -0.472
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APPENDIX I 
RAW DATA – SKELETAL MUSCLE TROPONIN I 
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Group 
Pre 
Sup 
Post 
Sup 
0 hr  
Post-Run 
2 hr  
Post-Run 
24 hr  
Post-Run 
Placebo 5.5 8.3 15.4 23.2 37.4 
Placebo 9.2 7.2 12.3 19.4 39.3 
Placebo 6.8 8.3 17.4 26.3 40.2 
Placebo 14.4 12.4 19.3 24.2 39.3 
Placebo 3.3 2.8 7.3 13.3 21.4 
Placebo 4.7 6.3 13.7 15.3 24.3 
Placebo 11.6 13.4 17.4 20.2 31.4 
Placebo 8.2 5.3 9.6 13.2 24.3 
Placebo 11.8 7.3 12.1 14.8 18.4 
Placebo 6.3 4.2 7.4 9.5 31.4 
Placebo 6.7 4.8 7.1 14.3 35.3 
Placebo 5.9 4.2 10.4 12.6 14.3 
Placebo 9.8 10.3 18.3 23.2 39.3 
Placebo 11.1 12.4 19.4 26.4 41.3 
Placebo 7.4 4.7 8.3 11.3 19.4 
Placebo 11.1 12.4 16.4 19.7 26.4 
Mean: 8.4 7.8 13.2 17.9 30.2 
SD: 3.1 3.5 4.5 5.6 9 
CV: 0.369 0.449 0.341 0.313 0.298 
Treatment 6.3 8.3 11.3 17.5 10.85 
Treatment 13.2 12.4 15.3 20.3 26.5 
Treatment 5.2 2.8 6.4 12.6 19.3 
Treatment 8.9 5.6 8.4 9.5 25.3 
Treatment 7.4 5.6 9.3 11.2 19.6 
Treatment 9.6 11.2 14.4 17.5 23.4 
Treatment 12.4 13.2 19.4 18.4 24.3 
Treatment 13.7 14.2 17.3 16.5 26.4 
Treatment 3.8 2.9 6.4 9.5 19.4 
Treatment 4.2 3.2 5.3 8.4 17.5 
Treatment 5.7 4.2 7.3 7.9 10.3 
Treatment 5.8 5.2 9.8 10.3 12.6 
Treatment 6.9 6 12.6 18.3 31.5 
Treatment 10.2 9.2 12.3 14.3 17.5 
Treatment 3.1 3.8 5.9 14.3 23.4 
Treatment 6.3 6.1 9.5 9.2 17.4 
Mean: 7.7 7.1 10.7 13.5 20.3 
SD: 3.3 3.8 4.2 4.2 6 
CV: 0.429 0.535 0.393 0.311 0.296 
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Group 
48 hr  
Post-Run 
72 hr  
Post-Run 
96 hr  
Post-Run 
Placebo 34.2 31.3 28.4 
Placebo 26.3 23.5 12.4 
Placebo 36.3 35.3 30.3 
Placebo 31.3 29.2 22.5 
Placebo 25.3 20.3 6.5 
Placebo 27.4 23.8 24.8 
Placebo 33.2 28.4 19.4 
Placebo 24.3 19.4 8.6 
Placebo 19.4 14.5 6.7 
Placebo 26.5 19.3 12.5 
Placebo 31.3 24.4 18.3 
Placebo 13.4 9.4 7.4 
Placebo 34.5 25.6 20.4 
Placebo 39.4 32.4 25.6 
Placebo 17.4 17.9 14.5 
Placebo 27.3 22.5 9.5 
Mean: 28 23.6 16.7 
SD: 7.1 6.8 8.1 
CV: 0.254 0.288 0.485 
Treatment 8.5 12.5 7.4 
Treatment 22.4 20.4 10.5 
Treatment 15.4 13.5 12.3 
Treatment 22.1 15.6 13.5 
Treatment 15.9 17.6 8.9 
Treatment 19.3 12.4 5.3 
Treatment 19.4 18.5 6.9 
Treatment 25.4 24.5 19.5 
Treatment 24.3 22.9 17.5 
Treatment 16.4 15.4 12.5 
Treatment 12.4 13.5 5.6 
Treatment 13.2 11.4 7.6 
Treatment 29.4 28.5 26.4 
Treatment 14.7 12.2 10.3 
Treatment 25.3 16.4 7.6 
Treatment 13.5 12.6 10.3 
Mean: 18.6 16.7 11.4 
SD: 5.8 5 5.7 
CV: 0.312 0.299 0.5 
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